To establish a regulatory framework for in vitro clinical tests that advances innovation for patient benefit, protects patients, provides a predictable and timely path to market, ensures reasonable risk-based regulation, avoids duplicative regulation, advances precision medicine, and applies the same regulatory principles to the same activity regardless of entity type, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mr. Bucshon (for himself and Ms. DeGette) introduced the following bill; which was referred to the Committee on ____________________________

A BILL

To establish a regulatory framework for in vitro clinical tests that advances innovation for patient benefit, protects patients, provides a predictable and timely path to market, ensures reasonable risk-based regulation, avoids duplicative regulation, advances precision medicine, and applies the same regulatory principles to the same activity regardless of entity type, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

(a) **Short Title.**—This Act may be cited as the “Diagnostic Accuracy and Innovation Act”.

(b) **Table of Contents.**—The table of contents of this Act is as follows:

- Sec. 1. Short title; table of contents.
- Sec. 2. In vitro clinical tests defined.
- Sec. 3. Regulation of in vitro clinical tests.
- Sec. 4. FDA fees.
- Sec. 5. Certification of laboratories (CLIA).
- Sec. 6. Transitional provisions.

SEC. 2. IN VITRO CLINICAL TESTS DEFINED.

(a) **Definitions.**—Section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321) is amended by adding at the end the following:

“(ss)(1) The term ‘in vitro clinical test’—

“(A) means a laboratory test protocol or finished product intended by its developer to be used in the collection, preparation, analysis, or in vitro clinical examination of specimens taken or derived from the human body for the purpose of identifying, screening, measuring, detecting, predicting, monitoring, or assisting in selecting treatment for, a disease or other condition;

“(B) excludes any test that—

“(i) meets the definition of a ‘biological product’ under section 351 of the Public Health Service Act; and
“(ii) is intended to—

“(I) screen human blood, human cells, tissues, cellular or tissue-based products (HCT/Ps), or organs for infectious diseases; or

“(II) determine the compatibility of a donor or patient to ensure the safe transfusion or transplantation of blood, human cells, tissues, cellular or tissue-based products (HCT/Ps), or organs; and

“(C) excludes any test intended by its developer solely for nonclinical use.

“(2) The term ‘laboratory test protocol’—

“(A) means the final design of a test not produced, provided, purchased, or sold as a finished product; and

“(B) excludes laboratory operations (as defined in section 353(a)(3) of the Public Health Service Act).

“(3) The term ‘finished product’—

“(A) means any article of personal property other than a laboratory test protocol that is suitable, and capable of functioning, for its intended use as described in paragraph (1)(A) without further production activity; and
“(B) excludes any component, part, or raw material.”.

(b) EXCLUSION FROM DEFINITIONS OF DRUGS, DEVICES, AND BIOLOGICAL PRODUCTS.—

(1) Drug definition.—Section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)) is amended by striking “means” and inserting “excludes any in vitro clinical test and any component, part, raw material, or accessory of an in vitro clinical test and means”.

(2) Device definition.—Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)) is amended by striking “means” and inserting “excludes any in vitro clinical test and any component, part, raw material, or accessory of an in vitro clinical test and means”.

(3) Biological product.—Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended by striking “means” and inserting “excludes any in vitro clinical test and any component, part, raw material, or accessory of an in vitro clinical test and means”.
SEC. 3. REGULATION OF IN VITRO CLINICAL TESTS.

(a) IN GENERAL.—Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at the end the following new subchapter:

“Subchapter J—In Vitro Clinical Tests

“SEC. 590. REGULATION OF IN VITRO CLINICAL TEST DEVELOPMENT ACTIVITIES.

“(a) IN GENERAL.—The Secretary of Health and Human Services shall, in accordance with the provisions of this subtitle, establish procedures and processes for the regulation of in vitro clinical tests.

“(b) SCOPE OF AUTHORITY.—

“(1) IN GENERAL.—The design, development, validation, production, manufacture, preparation, propagation, assembly, and modification of an in vitro clinical test—

“(A) shall be regulated by the Secretary under this subchapter; and

“(B) shall not be regulated by the Secretary under section 353 of the Public Health Service Act.

“(2) LIMITATIONS.—

“(A) LABORATORY OPERATIONS.—The provisions of this subchapter shall not apply to laboratory operations, as defined in section 353 of the Public Health Service Act.
“(B) Public health surveillance activities.—

“(i) In general.—The provisions of this subchapter shall not apply to a test intended to be used solely for public health surveillance.

“(ii) Definition.—In this subparagraph, the term ‘public health surveillance’ means ongoing systematic activities, including collection, analysis, and interpretation of health-related data, essential to planning, implementing, and evaluating public health practice.

“(C) Other limitations.—Nothing in this subchapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe, order, or use the results of an in vitro clinical test with respect to a patient for any purpose within a health care practitioner-patient relationship, as defined by applicable State law.

“(c) Agency center.—Not later than 90 calendar days after the date of enactment of the Diagnostic Accuracy and Innovation Act, the Secretary shall establish within the Food and Drug Administration the Center for
In Vitro Clinical Tests, which shall report to the Commissioner of Food and Drugs in the same manner as the other agency centers within the Food and Drug Administration. The Center shall be responsible for the implementation of this subchapter and closely related matters assigned by the Commissioner. Senior management of the Center shall include at least one person with management experience in clinical laboratory operations and at least one person with management experience in the development or commercialization of finished products.

“(d) DEFINITIONS.—In this subchapter:

“(1) The terms ‘analytical validity’ and ‘analytically valid’ mean, with respect to an in vitro clinical test, the ability of the in vitro clinical test—

“(A) to identify, measure, detect, calculate, or analyze one or more analytes, biomarkers, substances, or other targets intended to be identified, measured, detected, calculated, or analyzed by the test; or

“(B) as applicable, the ability of the in vitro clinical test to assist in such identification, measurement, detection, calculation, or analysis, as claimed by the developer.

“(2) The terms ‘clinical validity’ and ‘clinically valid’—
“(A) mean, with respect to an in vitro clinical test, the reliability and accuracy with which
the test, as claimed by the developer—

“(i) identifies, screens, measures, detects, calculates, predicts, monitors, or assists in selecting treatment for, a disease
or other condition in humans;

“(ii) identifies, screens, measures, detects, predicts, or monitors characteristics related to an individual’s clinical status; or

“(iii) as applicable, assists in such identification, screening, measurement, detection, calculation, or analysis; and

“(B) exclude clinical utility.

“(3) The term ‘developer’ means the person responsible for the design, development, validation, production, manufacture, preparation, propagation, assembly, or initial importation of an in vitro clinical test.

“(4) The terms ‘laboratory’, ‘laboratory operations’, and ‘standard operating procedures’ have the meanings given to such terms in section 353(a)(3) of the Public Health Service Act.

“(5) The term ‘mitigating measures’ means, with respect to an in vitro clinical test, one or more
measures that the Secretary determines, based on available evidence, are necessary to provide a reasonable assurance of the analytical validity and clinical validity, or probable clinical validity, as applicable, of an in vitro clinical test for its intended use, in a particular risk classification.

“(6) The term ‘modification’, with respect to an in vitro clinical test—

“(A) means—

“(i) any change to a finished product; or

“(ii) a change to the design or intended use of a laboratory test protocol;

“(B) excludes any change to, or activity that constitutes, laboratory operations; and

“(C) excludes any activity that constitutes the practice of medicine.

“(7) The term ‘offer’ means to make available for purchase, order, prescription, or use.

“(8) The term ‘platform’ means an in vitro clinical test that is hardware intended by the hardware’s developer to be used with one or more in vitro clinical tests to generate a clinical test result, including software used to effectuate the hardware’s functionality.
“(9) The term ‘probable clinical validity’ means, based on currently available evidence with respect to an in vitro clinical test, it is more likely than not that the in vitro clinical test is clinically valid.

“(10) The term ‘rare disease in vitro clinical test’—

“(A) means an in vitro clinical test intended to identify, measure, detect, predict, monitor, or assist in selecting treatment for a disease or condition with an incidence of 8,000 or fewer per year or a prevalence of 50,000 or fewer in the United States; and

“(B) excludes an in vitro clinical test intended solely for the screening of asymptomatic patients or predicting the occurrence of a future disease or condition in asymptomatic patients.

“(11)(A) The term ‘reasonable assurance’ means the degree of valid scientific evidence for in vitro clinical tests needed to demonstrate analytical validity or clinical validity, for the intended use of the in vitro clinical test, as applicable, which may vary based upon the relevant—

“(i) population size;

“(ii) disease or condition;

“(iii) demographic representation;
“(iv) type of use claim (such as predictive, prognostic, diagnostic, monitoring, treatment selection, and screening uses);

“(v) risk classification;

“(vi) availability of warnings and restrictions or other mitigating measures;

“(vii) use environment;

“(viii) user;

“(ix) feasibility of data collection, including for example as may be affected by disease or condition prevalence;

“(x) impact of requiring additional data collection on innovation;

“(xi) experience with similar in vitro clinical tests;

“(xii) ease of use; or

“(xiii) other factors.

“(B) There is reasonable assurance of the analytical validity and clinical validity of an in vitro clinical test when it can be determined, based upon valid scientific evidence, that the use of the in vitro clinical test for its intended use will provide results that are analytically valid and clinically valid in a significant portion of the intended-use population.
“(12)(A) The term ‘valid scientific evidence’ means, with respect to an in vitro clinical test, evidence—

“(i) which has been generated and evaluated by persons qualified by training or experience to do so, using procedures generally accepted by other persons so qualified; and

“(ii) from which it can be fairly and responsibly concluded by qualified experts that there is a reasonable assurance of analytical validity and clinical validity, or probable clinical validity where applicable, of the in vitro clinical test for its intended use.

“(B) Subject to subparagraph (A), the term ‘valid scientific evidence’ may, with respect to an in vitro clinical test, include, alone or in combination—

“(i) peer-reviewed literature;

“(ii) clinical guidelines;

“(iii) reports of significant human experience with an in vitro clinical test;

“(iv) bench studies;

“(v) case studies or histories;

“(vi) clinical data;
“(vii) consensus standards;
“(viii) reference standards;
“(ix) data registries;
“(x) postmarket data;
“(xi) clinical trials; and
“(xii) data collected in countries other than the United States.

“SEC. 590A. CLASSIFICATION OF IN VITRO CLINICAL TESTS.

“(a) RISK CLASSIFICATION.—
“(1) IN GENERAL.—The Secretary shall, based on the intended use of an in vitro clinical test, establish the following risk classes and classify in vitro clinical tests within such classes in accordance with this section:
“(A) High-risk.
“(B) Moderate-risk.
“(C) Low-risk.
“(2) HIGH-RISK CLASS.—An in vitro clinical test shall be regulated as high-risk if—
“(A) a clinically significant inaccurate result for the intended use would cause serious or irreversible harm, prolonged disability, or death, to the patient or public based on a failure to treat, an incorrect treatment, or an invasive
procedure, if such inaccurate result were undetected when used as intended;

“(B) none of the factors specified in paragraph (5) has the capacity to prevent or detect such inaccurate result or otherwise mitigate the risk of such inaccurate result; and

“(C) the risk of adverse patient impact or adverse public health impact caused by an inaccurate result is not remote.

“(3) MODERATE-RISK CLASS.—An in vitro clinical test shall be regulated as moderate-risk if—

“(A) the test meets the criteria specified in paragraph (2)(A) for classification as high-risk, but one or more factors described in paragraph (5) has the capacity to prevent or detect the clinically significant inaccurate result or otherwise mitigate the risk; or

“(B)(i) a clinically significant inaccurate result for the intended use would cause non-life-threatening injury, injury that is medically reversible, or delay in necessary treatment if such inaccurate result were undetected when used as intended;

“(ii) none of the factors described in paragraph (5) has the capacity to prevent or detect
such inaccurate result or otherwise mitigate the risk of such inaccurate result; and

“(iii) the risk of adverse patient impact or adverse public health impact caused by an inaccurate result is not remote.

“(4) LOW-RISK CLASS.—An in vitro clinical test shall be regulated as low-risk if—

“(A) the test meets the criteria for classification as moderate-risk specified in paragraph (3)(B)(i), but one or more factors described in paragraph (5) has the capacity to prevent or detect the clinically significant inaccurate result or otherwise mitigate the risk;

“(B) a clinically significant inaccurate result for the intended use would cause minimal or no harm, immediately reversible harm, or no disability if such inaccurate result were undetected when used as intended; or

“(C) the risk of adverse patient impact or adverse public health impact caused by an inaccurate result is remote.

“(5) RISK REDUCING FACTORS.—A factor described in this paragraph is one of the following:

“(A) The in vitro clinical test’s technology and clinical use are well characterized.
“(B) Clinical circumstances in which the in vitro clinical test is used, including clinical presentation.

“(C) The availability of—

“(i) other tests, such as confirmatory or adjunctive tests; or

“(ii) relevant materials standards.

“(D) Such other factors as the Secretary considers necessary.

“(E) Mitigating measures.

“(b) PRECLASSIFICATION MEETING.—Before submitting a request under subsection (c) or (d) for classification or reclassification, as applicable, of an in vitro clinical test—

“(1) the developer of the test or any other interested person may submit to the Secretary a written request for a meeting to discuss and provide information relating to classification or reclassification of the test; and

“(2) upon receipt of such a request, the Secretary shall—

“(A) within 30 calendar days after such receipt, or by such later date as may be agreed to by the developer or other interested person submitting the request, meet with such devel-
oper or other interested person who submitted the request; and

“(B) within 30 calendar days after such meeting, provide a written record or response describing the issues discussed and conclusions reached in the meeting.

“(c) Classification Process.—

“(1) Classification by operation of law.—Subject to any reclassification made pursuant to subsection (d), if a type of in vitro clinical test has been classified by the Secretary under this section, and such classification remains in effect, any in vitro clinical test within such type is deemed to be in the same class.

“(2) Classification by Secretary.—

“(A) Submission of request.—In the case of an in vitro clinical test that is not classified pursuant to paragraph (1) or subsection (e), the developer of the in vitro clinical test or any other interested person may submit a request to the Secretary for classification of the in vitro clinical test.

“(B) Form of request.—A request under subparagraph (A) shall be in such form, submitted in such manner, and contain such in-
formation as the Secretary may require. At a minimum, any such request shall contain each of the following:

“(i) A detailed description of the in vitro clinical test, including its intended uses, a description of its composition, and an explanation of the mechanism by which it functions.

“(ii) A recommended classification, including a rationale for the recommended classification.

“(iii) Proposed mitigating measures, if any, and an explanation of how the proposed mitigating measures support the recommended classification.

“(C) Disposition of Request.—The Secretary shall—

“(i) not later than 60 calendar days after receiving a request under subparagraph (B), issue a written order—

“(I) rejecting, modifying, or accepting the recommended classification of the in vitro clinical test; and

“(II) explaining the reasons for such decision and in the case of a
modification or rejection of the recommended classification, the reason for the modification or rejection of the recommended classification, including the reasons why the information and explanations submitted by the developer or other interested person (including any valid scientific evidence relating to the in vitro clinical test involved) do not support the recommended classification; and

“(ii) not later than 60 calendar days after issuing an order under clause (i) with respect to a recommended classification for an in vitro clinical test, publish a notice in the Federal Register announcing the classification.

“(D) Failure to Issue Timely Order.—If the Secretary fails to issue an order under subparagraph (C) within the time period applicable under such subparagraph, the recommended classification submitted under subparagraph (B)(ii) shall be the final classification.
“(E) Classification Appeals.—In the case of a modification or rejection of a recom-
commended classification of an in vitro clinical test by order issued by the Secretary under sub-
paragraph (C)(i)—

“(i) such modification or rejection shall be treated as final and immediately subject to appeal by the developer or re-
questor under section 590F; and

“(ii) not later than 90 calendar days after the date on which such modification or rejection is issued, the developer of the test may, as part of such an appeal, obtain review of the recommended classification by an advisory panel.

“(3) Multiple Intended Uses.—If a single in vitro clinical test has multiple intended uses, any such test shall be classified based on the intended use with the highest risk class.

“(4) Accessories; Platforms.—

“(A) Accessories.—

“(i) In General.—An in vitro clinical test, that is intended by its developer to be used as an accessory to another in vitro clinical test, shall be classified according to
its intended use and independently of any
classification of any in vitro clinical test
with which it is intended to be used.

“(ii) DEFINITION.—In this subpara-
graph, the term ‘accessory’ means a stand-
alone item intended by its developer to be
used in conjunction with one or more par-
ticular in vitro clinical tests to enable or
assist that in vitro clinical test in per-
forming its intended use.

“(B) PLATFORMS.—A platform shall be
classified and regulated under this title sepa-
rately from the in vitro clinical test or tests
with which it is used and shall be classified as
low-risk. An in vitro clinical test intended to be
performed on the platform shall be classified
according to its intended use and independently
of the platform.

“(d) RECLASSIFICATION PROCESS.—
“(1) IN GENERAL.—Based on new information
respecting an in vitro clinical test when used in ac-
cordance with its intended use, the Secretary may,
upon the Secretary’s own initiative or upon petition
of an interested person, by administrative order pub-
lished in the Federal Register—
“(A) change such in vitro clinical test’s classification; and

“(B) revoke or revise, as appropriate, any regulation or requirement issued in connection with the in vitro clinical test’s previous classification, notwithstanding subchapter II of chapter 5 of title 5, United States Code.

“(2) Recommendations of Advisory Panel.—In publishing an order under paragraph (1)—

“(A) the Secretary may secure, or the interested person may require that the Secretary secure, from an advisory panel, a recommendation respecting the proposed change in the in vitro clinical test’s classification; and

“(B) the Secretary shall publish in the Federal Register any recommendation submitted to the Secretary by the panel respecting such change.

“(3) Membership of Advisory Panels.—Any advisory panel convened to review the classification change shall include persons with knowledge of in vitro clinical tests, laboratory operations, and the use of in vitro clinical tests.

“(4) Down-Classification.—
“(A) IN GENERAL.—If the Secretary, upon the Secretary’s own initiative or upon petition, intends to make a down-classification of an in vitro clinical test, the Secretary shall publish a notice in the Federal Register of such intent. Such notice shall—

“(i) if the Secretary intends to modify or add mitigating measures applicable to the test involved—

“(I) describe and provide justification for such mitigating measures; and

“(II) provide for a 90-calendar-day public comment period; and

“(ii) if the Secretary does not intend to modify or add any such mitigating measures, provide for a 60-calendar-day public comment period.

“(B) PREVENTION OF UP-CLASSIFICATION.—In the case of an in vitro clinical test that the Secretary determines would be up-classified but for the withdrawal, modification, or addition of mitigating measures applicable to an in vitro clinical test, the Secretary shall publish in the Federal Register a notice of the Sec-
retary’s intent to withdraw, modify, or add such mitigating measures. Such notice shall—

“(i) describe and provide justification for such mitigating measures; and

“(ii) provide for a 90-calendar-day public comment period.

“(C) FINAL DETERMINATION.—Not later than 60 calendar days after the close of the applicable public comment period under subparagraph (A) or (B), the Secretary shall—

“(i) decide whether to make the down-classification of the in vitro clinical test involved;

“(ii) publish a notice of such decision in the Federal Register;

“(iii) if the Secretary decides to make the down-classification, publish an administrative order—

“(I) in accordance with paragraph (1); and

“(II) describing and providing justifications for any mitigating measures applicable to such down-classification; and
“(iv) revoke or revise, as appropriate, any regulation or requirement issued in connection with the in vitro clinical test’s previous classification.

“(5) UP-CLASSIFICATION.—In the case of a proposed up-classification of an in vitro clinical test, the Secretary—

“(A) shall make the up-classification by written order in accordance with paragraph (1);

“(B) shall revoke or revise, as appropriate, any regulation or requirement issued in connection with the in vitro clinical test’s previous classification; and

“(C) shall not delegate authority to make the up-classification to any employee or official other than the chief scientific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center.

“(6) TRANSITION PERIOD.—When the Secretary establishes, adds, or modifies a mitigating measure, or makes a down-classification or up-classification, the Secretary shall provide an appropriate transition period with respect to—
“(A) in vitro clinical tests under premarket review; and

“(B) in vitro clinical tests not under premarket review, but for which the classification or mitigating measures are inconsistent with documented advice provided to the developer by the Food and Drug Administration.

“(7) RECLASSIFICATION APPEALS.—In the case of a modification or rejection of a recommended classification change of an in vitro clinical test under paragraph (1) or failure to make a determination with respect to a down-classification within the time-frame specified in paragraph (4)(C)—

“(A) such modification, rejection, or failure shall be treated as final and immediately subject to appeal under section 590F; and

“(B) upon request of the developer made not later than 180 calendar days after the date of such modification, rejection, or failure, the Secretary shall obtain the recommendation of an advisory panel with respect to the reclassification.

“(e) INITIAL CLASSIFICATION OF PREVIOUSLY CLASSIFIED IN VITRO CLINICAL TESTS.—
“(1) IN GENERAL.—An in vitro clinical test classified under section 513(a) as of the date of enactment of the Diagnostic Accuracy and Innovation Act shall be classified as follows:

“(A) An in vitro clinical test classified in class I under section 513(a)(1)(A), as of such date, is deemed to be classified as a low-risk in vitro clinical test.

“(B) An in vitro clinical test classified as class II under section 513(a)(1)(B), as of such date, is deemed to be classified as a moderate-risk in vitro clinical test.

“(C) An in vitro clinical test classified as class III under section 513(a)(1)(C), as of such date, is deemed to be classified as a high-risk in vitro clinical test.

“(2) CONTINUED APPLICATION OF MITIGATING MEASURES.—An in vitro clinical test described in paragraph (1) that is subject to one or more mitigating measures as of the date specified in such paragraph shall continue to be subject to such mitigating measures after such date, unless—

“(A) the classification of the test is changed under this subsection; or
“(B) the mitigating measures applicable to such classification are changed pursuant to this subsection.

“(3) PUBLIC COMMENT.—Not later than 60 calendar days after the date of enactment of the Diagnostic Accuracy and Innovation Act, the Secretary shall—

“(A) publish a notice in the Federal Register that—

“(i) identifies, with supporting scientific rationale, all in vitro clinical tests for which the Secretary believes the classification pursuant to paragraph (1) is incorrect;

“(ii) requests that interested persons—

“(I) notify the Secretary of any in vitro clinical test for which the interested person believes the classification pursuant to paragraph (1) is incorrect; and

“(II) provide supporting scientific rationale for such belief; and

“(iii) requests that interested persons—
“(I) notify the Secretary of any in vitro clinical test that was—

“(aa) offered as of the date that is 90 calendar days prior to the date of the enactment of the Diagnostic Accuracy and Innovation Act; and

“(bb) not classified under section 513(a) as of such date; and

“(II) provide a suggested classification with supporting scientific rationale; and

“(B) provide a 120-calendar-day public comment period with respect to such notice.

“(4) REVIEW AND RECOMMENDATIONS BY ADVISORY PANELS.—

“(A) IN GENERAL.—Not later than 90 calendar days after the date of enactment of the Diagnostic Accuracy and Innovation Act, the Secretary shall identify or establish one or more advisory panels (in this subsection referred to as an ‘advisory panel’)—

“(i) to review and consider the classification of each in vitro clinical test identi-
fied by the Secretary or an interested person pursuant to paragraph (3); and

“(ii) to recommend the appropriate classification of each such test in accordance with this section.

“(B) MEMBERSHIP.—The members of an advisory panel shall include a balanced representation of persons representing physicians, other health care professionals, consumers, and the in vitro clinical test manufacturing and laboratory industries.

“(C) INAPPLICABLE REQUIREMENTS.—Section 14 of the Federal Advisory Committee Act shall not apply for the duration of a panel established under this paragraph.

“(5) TIMING OF RECOMMENDATIONS.—

“(A) ASSIGNMENT TO ADVISORY PANEL.—Not later than 180 calendar days after the close of the public comment period under paragraph (3)(B) with respect to an in vitro clinical test, the Secretary shall direct the respective advisory panel to conduct the review required by paragraph (4).

“(B) ISSUANCE OF RECOMMENDATION.—Not later than 1 year after the Secretary di-
rects an advisory panel to review the classification of an in vitro clinical test under subparagraph (A), the advisory panel shall, after taking into consideration all public comments and, at the advisory panel’s discretion, holding public meetings, provide to the Secretary the advisory panel’s recommended classification of the in vitro clinical test.

“(6) CLASSIFICATION DETERMINATION.—

“(A) CLASSIFICATION.—Not later than 180 calendar days after the date on which the Secretary receives the recommendation of an advisory panel with respect to the classification of an in vitro clinical test under paragraph (5), the Secretary shall by administrative order published in the Federal Register—

“(i) classify the in vitro clinical test in accordance with the classes specified in this section and publish such classification in the Federal Register;

“(ii) if such classification differs from the classification recommended by the advisory panel, specifically rebut the advisory’s panel’s classification with scientific evidence;
“(iii) in the case of an up-classification, include a public health justification demonstrating the need for up-classification; and

“(iv) subject to a final classification determination under subparagraph (C)(iii), revoke or revise, as appropriate, any regulation or requirement issued in connection with the in vitro clinical test’s previous classification, notwithstanding subchapter II of chapter 5 of title 5, United States Code.

“(B) Finality of Classification.—Subject to subparagraph (C), a classification under subparagraph (A)(i) is deemed to be final upon publication.

“(C) Exception for Up-classification.—With respect to any up-classification published under subparagraph (A), the Secretary—

“(i) shall provide a 60-calendar-day period for public comment;

“(ii) shall not delegate authority to make the up-classification to any employee or official other than the chief scientific of-
ficer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center; and

“(iii) not later than 90 calendar days after the close of the public comment period under clause (i), shall publish in the Federal Register the final classification for such in vitro clinical test by written order published in the Federal Register classify the in vitro clinical test and revoke or revise, as appropriate, any regulation or requirement issued in connection with the in vitro clinical test’s previous classification, notwithstanding subchapter II of chapter 5 of title 5, United States Code.

“(7) Inaction by the Secretary.—If the Secretary fails to issue a final classification determination for an in vitro clinical test or type of in vitro clinical test within the timeframes described in paragraph (6), the recommendation of the respective advisory panel under paragraph (5) shall be the final classification for the in vitro clinical test or type of in vitro clinical test.

“(8) Deemed classification to become final.—The deemed classification under paragraph
(1) shall be the final classification of any in vitro clinical test or type of in vitro clinical test not submitted to an advisory panel pursuant to paragraph (5).

“(9) APPEAL OF CLASSIFICATION.—Not later than 60 calendar days after the date of the final classification of an in vitro clinical test under paragraph (6) or (7), the developer of the test may appeal such classification under section 590F.

“(f) OTHER ADDITIONS OR CHANGES TO MITIGATING MEASURES.—If the Secretary intends to modify or add mitigating measures other than as described in subsection (d), the Secretary shall—

“(1) describe and provide justification for such modification or addition; and

“(2) provide a 90-calendar-day public comment period on such modification or addition.

“(g) DEFINITIONS.—In this section:

“(1) DOWN-CLASSIFICATION.—The term ‘down-classification’ means—

“(A) reclassification from high-risk to moderate- or low-risk; or

“(B) reclassification from moderate-risk to low-risk.
“(2) **UP-CLASSIFICATION.**—The term ‘up-classification’ means—

“(A) reclassification from low-risk to moderate- or high-risk; or

“(B) reclassification from moderate-risk to high-risk.

“(3) **WELL-CHARACTERIZED.**—The term ‘well-characterized’ means well-established and well-recognized by the scientific or clinical community, as evidenced by one or more of the following:

“(A) Literature.

“(B) Practice guidelines.

“(C) Consensus standards.

“(D) Recognized standards of care.

“(E) Technology in use for many years.

“(F) Scientific publication by multiple sites.

“(G) Wide recognition or adoption by the scientific or clinical community.

“(H) Availability of proficiency testing.

**SEC. 590B. PREMARKET REVIEW.**

“(a) **IN GENERAL.**—The Secretary shall establish a process for the premarket review of in vitro clinical tests in accordance with this section.
“(b) Presubmission Meeting.—Before submitting an application under subsection (c) or (d) for offering an in vitro clinical test—

“(1) the developer of the test may submit to the Secretary a written request for a meeting or conference to discuss and provide information relating to the submission process and the type and amount of evidence expected to demonstrate a reasonable assurance of analytical validity and clinical validity, or probable clinical validity, as applicable; and

“(2) upon receipt of such a request, the Secretary shall—

“(A) within 30 calendar days after such receipt, or within such time period as may be agreed to by the developer, meet or confer with the developer submitting the request; and

“(B) within 30 calendar days after such meeting or conference, provide to the developer a written record or response describing the issues discussed and conclusions reached in the meeting.

“(c) Premarket Approval of High-Risk Tests.—

“(1) In General.—Subject to disapproval under subsection (g), the Secretary shall approve a
high-risk in vitro clinical test (other than an in vitro clinical test submitted for approval under subsection (f)) if, upon the submission to the Secretary of an application by the developer of the test, the Secretary determines that the application demonstrates a reasonable assurance that the in vitro clinical test is analytically valid and clinically valid for its intended use. The Secretary shall, by regulation, develop a process for such review and approval.

“(2) Application contents.—An application submitted with respect to an in vitro clinical test under paragraph (1) shall include—

“(A) the name, address, and establishment registration number of the developer of the test;

“(B) in the case of an application submitted by a person other than the developer, the name, address, and establishment registration number, if applicable, of the applicant;

“(C) the name of the in vitro clinical test;

“(D) the intended use of the in vitro clinical test;

“(E) a summary description of the in vitro clinical test, including as applicable—

“(i) the analyte, biomarker, substance, or other target sought to be identified,
measured, detected, calculated, or analyzed by the test;

“(ii) the specifications of the test;

“(iii) specimen types to be analyzed by the test;

“(iv) the indications for use of the test;

“(v) the intended users of, and user environments for, the test;

“(vi) brief descriptions of components of the test;

“(vii) principles of properties of the test or the principles of operation of the test;

“(viii) the software necessary for application of the test, including risk mitigation for cybersecurity;

“(ix) any quality control material recommendations, as applicable, for the use of the test; and

“(x) the method of specimen collection and transport to be used with the test, as applicable;

“(F) applicable performance standards, voluntary standards, or mitigating measures re-
lied upon by the developer in determining the analytical validity and clinical validity of the test;

“(G) a summary of design controls for the test and a declaration of the developer’s conformity to such design controls;

“(H) in the case of an in vitro clinical test that is a finished product, a summary of relevant process controls used in manufacturing the test, a validation master plan for such process, any acceptance activities or statistical techniques used to ensure the validity of results generated by the test, and any purchasing controls applicable to the test;

“(I) proposed labeling for the test, which shall—

“(i) account for the differences between an in vitro clinical test that is a laboratory test protocol and an in vitro clinical test that is a finished product, as appropriate; and

“(ii) except to the extent that such instructions are standard operating procedures as defined in section 353 of the Public Health Service Act, provide instructions
that relate to protection of the individual
performing the test, including, as appro-
priate, disinfection, sterility, electrical saf-
ty, and sample handling;

“(J) a risk assessment for the test;

“(K) a statement attesting to the truthful-
ness and accuracy of the submission; and

“(L)(i) a summary of the valid scientific
evidence that is relevant to determining whether
or not there is a reasonable assurance of ana-
lytical validity and clinical validity for the in-
tended use of the in vitro clinical test; and

“(ii) the protocol and summary of results
and conclusions from any studies performed
with respect to such test, including, as required
by paragraph (3), the raw data from such stud-
ies.

“(3) Submission of raw data from stud-
ies.—The Secretary shall by regulation—

“(A) set forth instances in which raw data
is not required to be submitted;

“(B) subject to subparagraph (C), only re-
quire the submission of raw data to the extent
necessary to address one or more questions—
“(i) directly raised in the relevant application; and

“(ii) directly related to the reasonable assurance of analytical validity and clinical validity of the in vitro clinical test for the intended use;

“(C) provide for submission of raw data to address a question directly related to the reasonable assurance of analytical validity and clinical validity of the intended use but not directly raised in the relevant application only if the Secretary demonstrates in writing signed by the chief scientific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center that the raw data is necessary to address a public health risk first arising after the date the application was submitted;

“(D) provide for the submission of raw data in the least onerous and most efficient manner sufficient to demonstrate a reasonable;

“(E) limit the data required to be submitted to data in the possession of the developer or its agent unless the Secretary demonstrates in writing signed by the chief sci-
entific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center that data necessary to establish a reasonable assurance of analytical validity, a reasonable assurance of clinical validity, or, as applicable, probable clinical validity, cannot otherwise be obtained for the intended use; and

“(F) limit the Secretary’s use of submitted raw data to analysis of reasonable assurance of analytical validity and clinical validity for the intended use and require that such use be in conformance with predefined acceptance criteria, if any.

“(4) APPROVAL PROCESS.—Not later than 120 calendar days after the date on which an application is submitted under paragraph (1), the Secretary shall—

“(A) issue an order approving or disapproving the application; and

“(B) in the case of an order disapproving the application, specify in such order the scientific rationale for such disapproval and the measures required to place such application in approvable form.
“(d) Premarket Approval of Moderate-Risk Tests.—

“(1) In general.—Subject to disapproval under subsection (g), the Secretary shall approve a moderate-risk in vitro clinical test (other than an in vitro clinical test submitted for approval under subsection (f)) if, upon the submission to the Secretary of an application by the developer of the test, the Secretary determines that the application demonstrates a reasonable assurance that the in vitro clinical test is analytically valid and clinically valid for its intended use. The Secretary shall, by regulation, develop a process for such review and approval.

“(2) Application contents.—An application submitted under paragraph (1) with respect to a moderate-risk in vitro clinical test shall include—

“(A) the name, address, and establishment registration number of the developer of the test;

“(B) in the case of an application submitted by a person other than the developer, the name, address, and establishment registration number, if applicable, of the applicant;

“(C) the name of the in vitro clinical test;

“(D) the intended use of the in vitro clinical test;
“(E) a summary description of the in vitro clinical test, including as applicable—

“(i) the analyte, biomarker, substance, or other target sought to be identified, measured, detected, calculated, or analyzed by the test;

“(ii) the specifications of the test;

“(iii) specimen types to be analyzed by the test;

“(iv) the indications for use of the test;

“(v) the intended users of, and user environments for, the test;

“(vi) brief descriptions of components of the test;

“(vii) principles of properties of the test or the principles of operation of the test;

“(viii) the software necessary for application of the test, including risk mitigation for cybersecurity;

“(ix) any quality control material recommendations, as applicable, for the use of the test; and
“(x) the method of specimen collection
and transport to be used with the test, as
applicable;
“(F) applicable performance standards,
voluntary standards, or mitigating measures re-
lied upon by the developer in determining the
analytical validity and clinical validity of the
test;
“(G) a declaration of the developer’s con-
formity to design controls;
“(H) proposed labeling for the test, which
shall—
“(i) account for the differences be-
tween an in vitro clinical test that is a lab-
oratory test protocol and an in vitro clin-
ical test that is a finished product, as ap-
propriate; and
“(ii) except to the extent that such in-
structions are standard operating proce-
dures as defined in section 353 of the Pub-
lic Health Service Act, provide instructions
that relate to protection of the individual
performing the test, including, as appro-
priate, disinfection, sterility, electrical safe-
ty, and sample handling;
“(I) a summary of the risk assessment for the test;

“(J) a statement attesting to the truthfulness and accuracy of the submission; and

“(K)(i) a summary of the valid scientific evidence that is relevant to determining whether or not there is a reasonable assurance of analytical validity and clinical validity for the intended use of the in vitro clinical test; and

“(ii) a summary of the protocol and summary of results and conclusions from any studies performed with respect to such test, including, as required by paragraph (3), the raw data from such studies.

“(3) Submission of raw data from studies.—The Secretary shall not require that raw data from studies described in paragraph (2)(K)(ii) be routinely submitted. Subject to the preceding sentence, the Secretary shall by regulation—

“(A) set forth instances in which raw data is required to be submitted;

“(B) require the submission of raw data only if the chief scientific officer of the Center for In Vitro Clinical Tests or another member
of the senior management of such Center demonstrates in writing that—

“(i) such data is necessary to address one or more questions directly related to clinical validity of an in vitro clinical of an in vitro clinical test with a new intended use or utilizing a new technology; and

“(ii) the requested data or equivalent information is not reasonably available by other means, including peer reviewed journals;

“(C) provide for the submission of raw data in the least onerous, most efficient manner sufficient to demonstrate a reasonable assurance of clinical validity, or, as applicable, probable clinical validity;

“(D) limit the data required to be submitted to data in the possession of the developer or its agent unless the Secretary demonstrates in writing signed by the chief scientific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center that data necessary to establish a reasonable assurance of clinical valid-
ity, or, as applicable, probable clinical validity, cannot otherwise be obtained; and

“(E) limit the Secretary’s use of submitted raw data to analysis of clinical validity and require that such use be in conformance with any predefined acceptance criteria.

“(4) APPROVAL PROCESS.—Not later than 75 calendar days after the date on which an application is submitted under paragraph (1), the Secretary shall—

“(A) issue an order approving or disapproving the application; and

“(B) in the case of an order disapproving the application, specify in such order the scientific rationale for such disapproval and the measures required to place such application in approvable form.

“(5) FAILURE TO ACT.—If the Secretary fails to issue an order under paragraph (4)(A) within the 75-calendar-day period specified in such paragraph with respect to an in vitro clinical test, the in vitro clinical test may be legally marketed by the developer without further action by the Secretary and for purposes of this Act shall be treated as having an approved application in effect under this subsection.
“(6) Third-party review process.—For purposes of reviewing applications submitted under paragraph (1), the Secretary shall establish by regulation a process under which—

“(A) third parties may conduct such review at the request of the developer;

“(B) the Secretary agrees or disagrees with a third-party reviewer’s conclusion that the developer has demonstrated a reasonable assurance of analytical validity and clinical validity or, as applicable, probable clinical validity for the intended use of the in vitro clinical test; and

“(C) if the Secretary disagrees with the third-party reviewer’s conclusion, the Secretary must provide the developer with a written justification for such decision.

“(e) Listing of low-risk and rare disease tests.—A low-risk in vitro clinical test or rare disease in vitro clinical test may be legally marketed by the developer without further action by the Secretary and shall be treated as having an approved application in effect under this section so long as the developer of the test lists the test with the Secretary in accordance with subsection (o).

“(f) Special pathway for certain tests.—
“(1) STANDARD.—In lieu of approving under subsection (c) or (d) a high- or moderate-risk in vitro clinical test described in paragraph (2), the Secretary, subject to subsection (g), shall as applicable—

“(A) approve such an in vitro clinical test under this subsection without confirmatory postmarket obligations if the developer of the test submits an application demonstrating a reasonable assurance of—

“(i) analytical validity for its intended use; and

“(ii) clinical validity for its intended use;

“(B) approve such an in vitro clinical test under this subsection subject to confirmatory postmarket obligations under paragraph (6) if the developer of the test submits an application demonstrating—

“(i) a reasonable assurance of analytical validity for its intended use; and

“(ii) probable clinical validity for its intended use; and

“(C) continue an approval under subparagraph (B) in effect without confirmatory
postmarket obligations under such subpara-
graph if the developer of the test submits a sup-
plemental application under paragraph (8) with
respect to the test and the Secretary —

“(i) finds that such application dem-
onstrates a reasonable assurance of clinical
validity for the intended use of the test; or

“(ii) does not disapprove the supple-
mental application under paragraph (9) by
the deadline applicable under such para-
graph.

“(2) ELIGIBILITY.—

“(A) IN GENERAL.—An in vitro clinical
test is eligible for approval or continuation of
approval, as applicable, under this subsection if
it is one of the following:

“(i) An unmet need in vitro clinical
test.

“(ii) A moderate-risk in vitro clinical
tests that offers a clinically significant ad-

vantage over in vitro clinical tests pre-

viously approved or cleared by the Sec-
retary or otherwise legally marketed.

“(B) EXCEPTIONS.—An in vitro clinical
test described in subparagraph (A) shall not be
eligible for approval or continuation of approval under this subsection if—

“(i) a supplemental application submitted by the developer or its affiliate for the in vitro clinical test was disapproved under paragraph (9); or

“(ii) an approval with confirmatory postmarket obligations under this subsection was—

“(I) granted to the developer or its affiliate for the in vitro clinical test; and

“(II) was withdrawn under paragraph (12).

“(3) ELECTION OF PATHWAYS.—If an in vitro clinical test is—

“(A) an unmet need in vitro clinical test,

“(B) a moderate-risk in vitro clinical test that offers a clinically significant advantage over in vitro clinical tests previously approved or cleared by the Secretary or otherwise legally marketed, or

“(C) an emergency use in vitro clinical test under section 564,
the developer of the test may elect to seek review of
the test under the pathway for any such applicable
category or combination of applicable categories.

“(4) APPLICATION CONTENTS.—The developer
of an in vitro clinical test seeking approval of the
test under this subsection shall submit an applica-
tion to the Secretary in accordance with the fol-
lowing:

“(A) If the in vitro clinical test is classified
as high-risk, and the developer seeks approval
under paragraph (1)(A), the application shall
include information described in subsection
(c)(2).

“(B) If the in vitro clinical test is classified
as moderate-risk, and the developer seeks ap-
proval under paragraph (1)(A), the application
shall include the information described in sub-
section (d)(2).

“(C) If the in vitro clinical test is classified
as high-risk or moderate-risk, and the developer
seeks approval under paragraph (1)(B), the ap-
lication shall include—

“(i) the information described in sub-
section (d)(2) that is needed to establish a
reasonable assurance of analytical validity
for its intended use; and

“(ii) a proposed plan for collection of
confirmatory postmarket evidence.

“(D) If the in vitro clinical test is classi-

cified as high-risk or moderate-risk, and the de-

developer seeks approval under paragraph (1)(C),
the application shall include the information
specifically required in the approved plan for
the collection of confirmatory postmarket evi-
dence demonstrating a reasonable assurance of
clinical validity.

“(5) APPROVAL PROCESS.—

“(A) IN GENERAL.—The Secretary shall—

“(i) issue an order approving or dis-

approving an application submitted under
paragraph (4)—

“(I) in the case of an unmet need

in vitro clinical test, not later than 30

calendar days after the date on which

such application is submitted; and

“(II) in the case of an in vitro

clinical test described in paragraph

(2)(A)(ii), not later than 75 calendar
days after the date on which such application is submitted;

“(ii) approve an application submitted under paragraph (4) unless the Secretary determines that a ground for disapproval of the application specified in subsection (g) applies; and

“(iii) in any order disapproving an application submitted under paragraph (4), specify the scientific rationale for the disapproval and the measures required to place such application in approvable form.

“(B) FAILURE TO APPROVE OR DISAPPROVE.—If the Secretary fails to issue an order approving or disapproving an application submitted under paragraph (4) within a time period applicable under subparagraph (A), the in vitro clinical test may be legally marketed by the developer, subject to the confirmatory postmarket obligations proposed by the developer in its application, without further action by the Secretary, and shall be treated as having an approved application in effect under this section.
“(6) CONFIRMATORY POSTMARKET OBLIGATIONS.—

“(A) AGREED UPON OBLIGATIONS.—If, pursuant to paragraph (1)(B), the Secretary approves an application that demonstrates a reasonable assurance that the in vitro clinical test is analytically valid for its intended use and demonstrates probable clinical validity for its intended use without demonstrating a reasonable assurance of clinical validity for its intended use—

“(i) the Secretary shall specify in the order granting such approval the confirmatory postmarket obligations agreed to by the Secretary and the developer of the test, including information and dates regarding the commencement and performance of such obligations;

“(ii) such confirmatory postmarket obligations—

“(I) shall facilitate the developer’s collection of additional valid scientific evidence as necessary to demonstrate a reasonable assurance
that the test is clinically valid for its intended use;

“(II) may include reporting requirements related to such obligations; and

“(iii) the developer shall complete the confirmatory postmarket obligations.

“(B) MODIFICATIONS TO OBLIGATIONS.—The confirmatory postmarket obligations agreed to under subparagraph (A) may be modified at any time by the mutual agreement of the Secretary and the developer.

“(C) LABEL REQUIREMENT.—An order approving an in vitro clinical test under paragraph (1)(B) shall require the labeling of the test to state the following: ‘Approved with confirmatory postmarket obligations’.

“(7) LAPSE OF APPROVAL.—

“(A) IN GENERAL.—An approval with confirmatory postmarket obligations under this subsection shall automatically lapse—

“(i) on the date that is three years after the date of such approval if an extension has not been granted by the Secretary and if the developer of the in vitro clinical
test has not submitted a supplemental application pursuant to paragraph (8) at least three months prior to such date;

“(ii) on the date specified in an extension order issued by the Secretary, if an extension is mutually agreed upon by the Secretary and the developer of the in vitro clinical test and if the developer has not submitted a supplemental application pursuant to paragraph (8) at least three months prior to the agreed upon extension date;

“(iii) on the date that is thirty calendar days after the date on which the Secretary issues an order disapproving a supplemental application submitted pursuant to paragraph (9) with respect to the in vitro clinical test, if the applicant does not appeal the order; or

“(iv) if the applicant submitting a supplemental application pursuant to paragraph (8) appeals an order disapproving the application, on the date on which the Director of the Center for In Vitro Clinical
Tests issues a decision upholding the dis-
approval.

“(B) DURATION OF EXTENSION.—The
term of any extension described in subpara-
graph (A)(ii) shall not extend beyond the date
that is four years after the date of approval
with confirmatory postmarket obligations for
the in vitro clinical test.

“(8) SUPPLEMENTAL APPLICATION.—The de-
veloper of an in vitro clinical test approved under
this subsection subject to confirmatory postmarket
obligations may submit a supplemental application
containing the contents specified in paragraph
(4)(D), as applicable, at any time prior to the dead-
line for submission under paragraph (7).

“(9) DISSAPPROVAL OF SUPPLEMENTAL APPLI-
CATION.—

“(A) IN GENERAL.—If the Secretary deter-
dines that a supplemental application sub-
mitted under paragraph (8) does not dem-
onstrate a reasonable assurance of clinical va-
\li
dity for the intended use of the in vitro clinical
test—

“(i) the Secretary shall, within 60 cal-
endar days after submission of such appli-
cation, issue an order disapproving the supplemental application;

“(ii) such order shall specify the scientific rationale for such decision; and

“(iii) such decision shall set forth a reasonable timeframe, not to exceed 30 calendar days, after which the developer of the in vitro clinical test shall cease to offer such test.

“(B) STAY OF DEADLINES.—A deadline set forth pursuant to subparagraph (A)(iii) shall be stayed during the pendency of an appeal under paragraph (10).

“(10) APPEAL OF DISAPPROVAL.—

“(A) IN GENERAL.—Not later than 30 calendar days after the date on which an initial decision is issued under paragraph (9) disapproving a supplemental application with respect to an in vitro clinical test, the developer of the test may appeal the disapproval directly to the Director of the Center for In Vitro Clinical Tests.

“(B) DETERMINATION OF DIRECTOR.—

The Director of the Center for In Vitro Clinical
Tests shall determine whether to uphold the disapproval that is the subject of the appeal—

“(i) not later than 45 calendar days after submission of the appeal; or

“(ii) if the developer requests in the appeal an in-person meeting or teleconference with the Director, not later than 30 calendar days after the date of such meeting or teleconference.

“(C) Effect of determination upholding disapproval.—If the Director of the Center for In Vitro Clinical Tests upholds a disapproval of a supplemental application under paragraph (9), such disapproval shall constitute final action by the Secretary and may not be appealed within the Food and Drug Administration.

“(11) Termination of postmarket obligations.—The approval of an in vitro clinical test under paragraph (1)(B) shall continue in effect as described in paragraph (1)(C), and any confirmatory postmarket obligations imposed under this subsection with respect to an in vitro clinical test, including the labeling requirement in paragraph (6)(C), shall terminate, if the Secretary approves a
supplemental application submitted under paragraph (8) with respect to the test.

“(12) WITHDRAWAL OF APPROVAL WITH CONFIRMATORY POSTMARKET OBLIGATIONS.—The Secretary may, after providing notice to the developer of the test and an opportunity for an informal hearing, withdraw an approval of an in vitro clinical test made subject to confirmatory postmarket obligations under this subsection at any time before such approval would otherwise lapse under this subsection if the Secretary determines, based on new valid scientific evidence, that—

“(A) the developer of the test can no longer demonstrate a reasonable assurance of the analytical validity, and probable clinical validity, of the test for its intended use; or

“(B) the test presents an unreasonable risk to human health.

“(13) PUBLIC DATABASE.—The Secretary may establish a public database that—

“(A) lists each in vitro clinical test approved subject to confirmatory postmarket obligations under this subsection;
“(B) may include, with respect to each such test, the end date and status of such confirmatory postmarket obligations; and

“(C) is updated to reflect any change in the status of such a test within 10 calendar days of that change in status.

“(14) INCENTIVES.—For in vitro clinical tests reviewed under this subsection, the Secretary shall—

“(A) provide review priority; and

“(B) provide additional personnel for review of applications.

“(15) DEFINITIONS.—In this subsection:

“(A) CLINICALLY SIGNIFICANT ADVANTAGE.—The term ‘clinically significant advantage’ means a reasonable potential to improve the ability to identify, measure, detect, predict, monitor, or assist in selecting treatment for a disease or other condition, including by providing for—

“(i) increased patient access;

“(ii) reduced sample size;

“(iii) expanded sample types;

“(iv) faster diagnosis;

“(v) improved analytical or clinical performance;
“(vi) less intrusive methods; or

“(vi) other improvements or benefit to patients or public health.

“(B) Unmet need in vitro clinical test.—The term ‘unmet need in vitro clinical test’ means an in vitro clinical test intended to be used to identify, measure, detect, predict, monitor, or assist in selecting treatment for, a serious or life-threatening disease or condition for which there is no approved or legally marketed in vitro clinical test with the same intended use.

“(16) Custom IVCTS.—A high-risk or moderate-risk in vitro clinical test shall not be subject to the requirements of subsection (c) or (d), or of paragraphs (1) through (15) of this subsection, if the test—

“(A) is developed or modified in order to comply with the order of an individual physician, dentist, or other health care professional (or any other specially qualified person designated under regulations promulgated by the Secretary after an opportunity for an oral hearing);
“(B)(i) is intended to meet the special needs of such physician, dentist, or other health care professional (or other specially qualified person so designated) in the course of the professional practice of such physician, dentist, or other health care professional; or

“(ii) is intended for use by an individual patient named in such order of such physician, dentist, or health care professional (or other specially qualified person so designated);

“(C) in order to comply with an order described in subparagraph (A), necessarily deviates from an otherwise applicable requirement under this section;

“(D) is not generally available in the United States in finished form for its intended use, as demonstrated through labeling or advertising by the developer, importer, or distributor of the test;

“(E) is designed to treat a unique pathology or physiological condition for which no other in vitro clinical test is available in the United States;

“(F) is developed, assembled from components, or manufactured and finished on a case-
by-case basis, to accommodate the unique needs
of a patient of a health care professional de-
scribed in subparagraph (A); and

“(G) may have standardized design charac-
teristics, chemical and material compositions,
and manufacturing processes in common with
commercially distributed in vitro clinical tests.

“(g) APPROVAL OF APPLICATIONS AND WITH-
dRAWAL OR SUSPENSION OF APPROVAL.—

“(1) APPROVAL.—

“(A) GROUNDS FOR DISAPPROVAL.—The
Secretary shall disapprove an application for an
in vitro clinical test under subsection (e), (d), or
(f) only if, upon the basis of the information
submitted to the Secretary as part of the appli-
cation and any other valid scientific evidence
before the Secretary with respect to such in
vitro clinical test, the Secretary finds that—

“(i) there is a lack of a showing of
reasonable assurance that such in vitro
clinical test is analytically valid and cli-

cally valid, or, as applicable under sub-
section (f), there is a lack of a showing of
a reasonable assurance of analytical valid-
ity and probable clinical validity for such
in vitro clinical test, for the intended uses
specified in the proposed labeling thereof;

“(ii) subject to subsection (h) (con-
cerning premarket inspections not being
required), the methods used in, or the fa-
cilities or controls used for, the manufac-
ture, packing, or installation of the in vitro
clinical test under review do not conform
to the requirements of section 590D and
such failures to conform with such require-
ments directly impact the analytical valid-
ity or clinical validity of the in vitro clinical
test under review for the intended uses set
forth in the proposed labeling thereof;

“(iii) based on a fair evaluation of all
material facts, the proposed labeling is
false or misleading in any particular or
otherwise does not provide adequate in-
structions for the use of the in vitro clin-
ical test for the intended uses specified in
the proposed labeling thereof;

“(iv) the application for such in vitro
clinical test under subsection (e), (d), or
(f) contains one or more material false
statements, and after being given an op-
portunity to correct such statements within a reasonable time, the applicant fails to do so;

“(v) the application for such in vitro clinical test demonstrates that the in vitro clinical test fails to satisfy an established mitigating measure required for such test pursuant to section 590A; or

“(vi) the application for such in vitro clinical test under subsection (c), (d), or (f) fails to include material information that is required to be part of the application, and, after being given an opportunity to correct such failure within a reasonable time, the applicant fails to do so.

“(B) RELIANCE ON PROPOSED LABELING.—In determining whether a ground for disapproval of an application specified in subparagraph (A) applies, the Secretary shall—

“(i) rely on the intended uses specified in the proposed labeling of the in vitro clinical test as the basis for determining whether there is a reasonable assurance of analytical validity and clinical validity, so
long as the proposed labeling is neither false nor misleading; and

“(ii) in determining whether such labeling is false or misleading, fairly evaluate all material facts pertinent to the proposed labeling.

“(C) Restrictions.—An order approving an application for an in vitro clinical test issued under subsection (e), (d), or (f) may require, as a condition on such approval, that a restriction to be imposed with respect to the sale and distribution of the in vitro clinical test, including a restriction that the test be used or performed only pursuant to a prescription, physician order, or order of another health care professional (as authorized by State law).

“(D) Acceptance of valid scientific evidence.—With respect to a determination on whether there is a reasonable assurance of analytical validity and clinical validity of an in vitro clinical test under subsection (e) or (d), or, as applicable under subsection (f), a reasonable assurance of analytical validity and probable clinical validity of an in vitro clinical test, the Sec-
retary shall accept and review valid scientific evidence—

“(i) derived from investigations of an earlier version of the in vitro clinical test, notwithstanding the in vitro clinical test having been modified during or after the investigations (but prior to submission of an application under subsection (c), (d), or (f)) if that modification does not constitute a significant change in the design or in the basic principles of operation of the in vitro clinical test that would invalidate the evidence; or

“(ii) relating to another in vitro clinical test approved under this section that is relevant to the design and intended use of the in vitro clinical test with respect to which the determination is being made.

“(E) POSTSUBMISSION MEETINGS.—

“(i) IN GENERAL.—The Secretary shall, upon the written request of an applicant submitting an application with respect to an in vitro clinical test under subsection (c), (d), or (f), meet with such applicant.
“(ii) Schedule.—Unless the Secretary and an applicant described in clause (i) mutually agree to an alternate schedule, a meeting requested under clause (i) shall be held—

“(I) in the case of a request with respect to a high-risk in vitro clinical test, meet with the applicant not later than 75 days after the receipt of the application under subsection (c) relating to such test;

“(II) in the case of a request with respect to a moderate-risk in vitro clinical test, meet with the applicant not later than 45 days after the receipt of the application under subsection (d) relating to such test;

“(III) in the case of an unmet need in vitro clinical test described in subsection (f)(2)(A)(i) for which an application is submitted under subsection (f), meet with the applicant not later than 15 days after the receipt of such application; and
“(IV) in the case of a moderate-risk in vitro clinical test described in subsection (f)(2)(A)(ii) for which an application is submitted under subsection (f), meet with the applicant not later than 30 after the receipt of such application.

“(iii) INFORMATION ON DEFICIENCIES.—Before the date on which any meeting is held pursuant to this subparagraph, the Secretary shall—

“(I) transmit in writing to the applicant requesting such meeting—

“(aa) a description of any deficiencies in the application involved that, as of such date, have been identified by the Secretary based on an interim review of the entire application;

“(bb) the statutory and regulatory requirements that the application is failing to meet; and

“(ce) the information that is required to correct the deficiencies so identified; and
“(II) notify the applicant promptly of—

“(aa) any deficiency identified by the Secretary that is not identified in the description transmitted to the applicant under subclause (I); or

“(bb) any additional information required to achieve completion of the review and final action on the application that was not included in the information transmitted under such subclause.

“(2) WITHDRAWAL AND TEMPORARY SUSPENSION OF APPROVAL OF APPLICATION.—

“(A) WITHDRAWAL.—The Secretary shall, upon obtaining, where appropriate, advice on scientific matters from a panel or panels, and after providing due notice and opportunity for an informal hearing to the holder of an approved application for an in vitro clinical test under this section, issue an order withdrawing approval of the application if the Secretary finds—
“(i) on the basis of new information before the Secretary with respect to such in vitro clinical test, evaluated together with the evidence available to the Secretary when the application was approved, that there is a lack of a showing of reasonable assurance of analytical validity and clinical validity, or probable clinical validity, as applicable, of the in vitro clinical test for its intended use;

“(ii) that the application contained or was accompanied by a material false statement;

“(iii) that the applicant—

“(I) failed to establish a system for maintaining records, or has repeatedly or deliberately failed to maintain records or to make reports, required under section 590E;

“(II) has refused to permit access to, or copying or verification of, such records as are required under section 704; or

“(III) has not complied with the requirements of section 590B;
“(iv) on the basis of new information before the Secretary with respect to a finished product, evaluated together with the evidence before the Secretary when the application was approved, that the methods used in, or the facilities and controls used for, the manufacture, processing, packing, or installation of such finished product do not conform with the applicable requirements under section 590D and were not brought into conformity with such requirements within a reasonable time after receipt of written notice from the Secretary of nonconformity;

“(v) on the basis of new information before the Secretary, evaluated together with the evidence before the Secretary when the application was approved, that the labeling of such in vitro clinical test, based on a fair evaluation of all material facts, is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the Secretary of such fact;
“(vi) on the basis of new information before the Secretary, evaluated together with the evidence before the Secretary when the application was approved, that such in vitro clinical test is not shown to conform in all material respects to an applicable performance standard or mitigating measure, which was part of the approval of the application and for which there is a lack of adequate information to justify the deviation from such standard; or

“(vii) in the case of a finished product, based upon a fair evaluation of all material facts, including the use environment and clinical role of the in vitro clinical test used in accordance with directions for use and warnings, the finished product presents an unreasonable risk of physical harm to the individual when conducting the test.

“(B) Review of order by hearing.— The holder of an application subject to an order issued under this paragraph withdrawing approval of the application may, by petition filed
on or before the 30th day after the date upon
which the holder receives notice of such with-
drawal, obtain review of such order by hearing
in accordance with section 554 of title 5,
United States Code.

“(C) Temporary Suspension.—If, after
providing an opportunity for an informal hear-
ing, the Secretary determines there is reason-
able probability that the continued offering of
an in vitro clinical test pursuant to an applica-
tion approved under this section would cause
serious, adverse health consequences or death,
the Secretary shall by order temporarily sus-
pend the approval of the application. If the Sec-
retary issues such an order, the Secretary shall
proceed expeditiously under this paragraph to
withdraw such application.

“(h) Premarket Inspections Not Required.—
The Secretary may not condition the approval of an applica-
tion under this section on the occurrence of a premarket
inspection or manufacturing review related to the applica-
tion. Nothing in the preceding sentence shall be construed
as limiting the authority of the Secretary to conduct qual-
ity system inspections under section 704 or other applicable
provisions of this Act.
“(i) **Laboratory Test Protocol Transfer or Sale.**—

“(1) **Listing Required.**—An in vitro clinical test that is a laboratory test protocol and approved under subsection (c), (d), or (f)(1) may be transferred, licensed, or sold to a third party for use pursuant to such approval, so long as, prior to the transfer, licensure, or sale, the party transferring, licensing, or selling the laboratory test protocol submits a supplement to its listing of such laboratory test protocol under subsection (o).

“(2) **Sharing Among Corporate Entities.**—

The supplemental listing requirement under paragraph (1) does not apply in the case of a transfer, licensure, or sale from an entity to another entity if—

“(A) the first entity controls or has the power to control the other entity;

“(B) the other entity controls or has the power to control the first entity; or

“(C) the two entities are under common ownership or control of a third entity.

“(3) **Effect of Laboratory Test Protocol Transfer.**—The transfer, license, or sale of less than the full right, title, and interest in a laboratory
test protocol, without transfer or sale of the approval, does not transfer the regulatory obligations of the developer under this subchapter to the transferee, licensee, or purchaser.

“(j) Transfer or Sale of Approval.—

“(1) Notice Required.—If a developer of an in vitro clinical test transfers or sells the approval of the test issued under subsection (c), (d), or (f)(1), the transferor or seller shall submit a notice of the transfer or sale to the Secretary.

“(2) Effect of Approval Transfer.—Upon completion of a transfer or sale described in paragraph (1), the transferee or purchaser shall have the regulatory obligations of the developer of the in vitro clinical test under this subchapter.

“(k) Justification for Requirement To Provide Evidence From Clinical Trials.—

“(1) Written Justification for Mandatory Clinical Trial.—The Secretary shall not require the developer of an in vitro clinical test to conduct a clinical trial as part of any application under this subchapter, unless such application is for approval of a high-risk in vitro clinical test and the Secretary submits to the developer written notice that—
“(A) provides a justification for such requirement, including an explanation of why the Secretary determines that, based on scientific or clinical criteria, other evidence is insufficient; and

“(B) is signed by the chief scientific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center.

“(2) WRITTEN JUSTIFICATION FOR OTHER CLINICAL STUDIES.—The Secretary shall not require the developer of an in vitro clinical test to conduct a clinical study other than a clinical trial as part of any application under this subchapter unless the Secretary submits to the developer written notice that—

“(A) provides a justification for such requirement, including an explanation of why the Secretary determines that, based on scientific or clinical criteria, other evidence is insufficient; and

“(B) is signed by the chief scientific officer of the Center for In Vitro Clinical Tests or another member of the senior management of such Center.
“(3) **Written Justification for Other Clinical Studies.**—The Secretary shall limit the size, scope, and nature of any clinical trial or other clinical study required pursuant to paragraph (1) or (2) to the size, scope, and nature necessary to establish the sufficient evidence not otherwise available, taking into consideration the feasibility of such clinical trial or other clinical study.

“(4) **Definition.**—For purposes of this subsection, the term ‘clinical trial’ means a well-controlled clinical study of prospectively collected human specimens that is performed to demonstrate or support clinical validity of the in vitro clinical test.

“(1) **Grandfathered Tests.**—

“(1) **In General.**—An in vitro clinical test first offered on a date that occurs before the date that is 90 calendar days prior to the date of enactment of the Diagnostic Accuracy and Innovation Act, and with respect to which the Secretary did not require an approval under section 515, a clearance under section 510(k), or a notification under section 510(j), or otherwise assert enforcement discretion under such sections, is legally marketed and is not
subject to premarket review under this section, ex-
cept as provided in paragraph (4), if the developer—

“(A) lists such in vitro clinical test in ac-
cordance with subsection (o)(3); and

“(B) with respect to a non-reviewed, high-
risk test, submits to the Secretary, not later
than 5 years after the date of enactment of the
Diagnostic Accuracy and Innovation Act, a
summary of available analytical validity and
clinical validity evidence.

“(2) CONTENTS OF SUMMARY.—A summary re-
quired by paragraph (1)(B)—

“(A) need not contain any evidence other
than existing evidence readily available to the
developer and shall be provided in summary
form; and

“(B) shall not be subject to a user fee
under section 4 of the Diagnostic Accuracy and
Innovation Act.

“(3) NO ADDITIONAL APPLICATION RE-
QUIRED.—The developer of an in vitro clinical test
that is described in paragraph (1) and listed in ac-
cordance with subsection (o) need not submit any
application for premarket approval of such test
under subsection (e), (d), or (f), except as provided
in paragraph (4).

“(4) Submission of certain tests.—

“(A) In general.—The Secretary shall
provide written notification to the developer of
an in vitro clinical test described in paragraph
(1) if, after creating a related administrative
file, the Secretary determines, based on all
available evidence, including a literature review,
that such in vitro clinical test—

“(i) presents an unreasonable and
substantial risk of death or serious adverse
health consequences when used as intended
by its developer; or

“(ii) is being offered by its developer
with materially deceptive or fraudulent an-
alytical or clinical claims.

“(B) Inclusion of basis for determination.—A notification under subparagraph
(A) shall set forth in detail the basis for the
Secretary’s determination.

“(C) Misbranding.—Upon receipt of a
written notification under subparagraph (A)—

“(i) the developer of such an in vitro
clinical test may avoid a finding of mis-
branding pursuant to clause (ii) by, not later than 120 calendar days after the date on which the developer receives such notification or by such later date as may be agreed to by the developer and the Secretary —

“(I) submitting a proposed plan and timeframe for addressing the concerns identified in the notification;

“(II) submitting a premarket submission for such test under subsection (c), (d), or (f), as applicable;

“(III) ceasing to offer such test;

“(IV) otherwise addressing the agency’s concerns; and

“(ii) if the developer fails (by the deadline applicable under clause (i)) to submit a plan, to submit an application, cease offering such test, or otherwise address the agency’s concerns as described in such clause, or if the Secretary disapproves any application so submitted, the in vitro clinical test is subject to a final agency action finding such in vitro test to be misbranded under section 502.
“(D) APPLICATION CONSIDERATIONS.—In reviewing a premarket submission submitted under subparagraph (C)(i)(II), the Secretary shall consider—

“(i) previously unpublished evidence provided by the developer submitting such application; and

“(ii) the developer’s description of the past experience with the in vitro clinical test.

“(E) TEMPORARY SALES PERIOD.—During the period of the review of a premarket submission submitted under subparagraph (C)(i)(II), the developer submitting such premarket submission with respect to an in vitro clinical test may continue to offer the test, without limitation, during the pendency of such submission and if such submission is disapproved, until the date specified by the Secretary.

“(5) DEFINITION.—In this subsection, the term ‘non-reviewed, high-risk test’ means an in vitro clinical test—

“(A) first offered on a date that occurs before the date that is 90 calendar days prior to the date of enactment of the Diagnostic Accu-
accuracy and Innovation Act, and with respect to which the Secretary did not require an approval under section 515, a clearance under section 510(k), or a notification under section 510(j), or otherwise assert enforcement discretion under such sections;

“(B) for which the developer does not hold an approval under section 515 or a clearance under section 510(k);

“(C) which has not been approved by a State pursuant to section 353 of the Public Health Service Act, including the New York State approval process established pursuant to part 58 of title 10 (relating to health) of the Official Compilation of Codes, Rules, and Regulations of the State of New York and any modifications to such process after the date of the enactment of the Diagnostic Accuracy and Innovation Act; and

“(D) which is classified as high-risk pursuant to section 590A(e).

“(m) IN VITRO CLINICAL TESTS WITH MARKETING AUTHORIZATION UNDER THE DEVICE AUTHORITIES.—If an in vitro clinical test received marketing authorization from the Food and Drug Administration as a device prior
to the date of enactment of the Diagnostic Accuracy and Innovation Act:

“(1) If the test was approved under section 515—

“(A) such test is deemed to have an approved application in effect under subsection (c); and

“(B) any conditions of approval or other requirements under section 515 specifically applicable to such test pursuant to such approval under section 515 shall continue to apply until the effective date of the regulations implementing this subchapter.

“(2) If the test was cleared under section 510(k)—

“(A) such test shall be deemed to have an approved application in effect under subsection (d); and

“(B) any requirements under section 510(k) specifically applicable to such test pursuant to such clearance shall continue to apply until the effective date of the regulations implementing this subchapter.

“(3) If the test was granted marketing authorization under section 513(f)(2)—
“(A) such test is deemed to have an approved application in effect under subsection (d); and

“(B) any conditions of approval or other requirements under section 513(f)(2) specifically applicable to such test pursuant to such authorization under section 513(f)(2) shall continue to apply until the effective date of the regulations implementing this subchapter.

“(n) PREMARKET REQUIREMENTS FOR MODIFICATIONS.—

“(1) IN GENERAL.—For purposes of this subchapter, a modification to an in vitro clinical test is subject to approval or listing as required by subsection (c), (d), (e), or (f) in accordance with the following:

“(A) In the case of a modification made with respect to a low-risk in vitro clinical test, the modification is subject to such process only if the modification—

“(i) changes the intended use or adds a new intended use such that the low-risk in vitro clinical test would be classified as moderate-risk or high-risk; or
“(ii) results in a meaningful clinical impact such that the test would be classified as a moderate-risk or high-risk test.

“(B) In the case of a modification made with respect to a moderate-risk in vitro clinical test, the modification is subject to such process only if the modification—

“(i) changes the intended use or adds a new intended use that is high-risk or moderate-risk; or

“(ii) results in a meaningful clinical impact.

“(C) In the case of a modification made with respect to a high-risk in vitro clinical test, the modification is subject to such process only if the modification—

“(i) changes the intended use or adds a new intended use of the test that is high-risk or moderate-risk; or

“(ii) results in a meaningful clinical impact.

“(2) TREATMENT OF MODIFIED CLASSIFICATION.—In the case of a modification described in paragraph (1), the applicable process for approval or listing of the in vitro clinical test with respect to
which the modification is made shall be determined in accordance with the risk classification of the test as so modified, unless validation and verification demonstrate that there is not a meaningful increase in risk to the patient or user for the intended uses compared to the risk assessment for the in vitro clinical test as previously approved.

“(3) NOTIFICATION.—If the risk assessment for the modification, prior to consideration of verification and validation and considering relevant existing mitigating measures, demonstrates that there is a meaningful and not remote increase in risk to the patient or user for the intended uses compared to the risk assessment for the in vitro clinical test as previously approved, but validation and verification demonstrate that there is not a meaningful increase in risk to the patient or user for the intended uses compared to the risk assessment for the in vitro clinical test as previously approved, the developer of the test shall, not later than the date on which such test is first offered as so modified, submit to the Secretary a notification of such modification. Such notification shall include—

“(A) the name of the in vitro clinical test;
“(B) a brief description of the modification;

“(C) a brief summary of the meaningful and not remote risks identified by the risk assessment described in such paragraph; and

“(D) a brief summary of the validation and verification methodologies or the mitigating measures used with respect to the test, including a brief summary of the results of validation and verifications studies performed with respect to the test.

“(4) EXCEPTION FOR MODIFICATIONS SATISFYING RECOGNIZED STANDARDS.—

“(A) IN GENERAL.—Notwithstanding paragraph (1), a premarket application shall not be required to be submitted under subsection (c), (d), or (f) with respect to a modification to a moderate-risk or high-risk in vitro clinical test if the developer of such test—

“(i) maintains records documenting that the modification—

“(I) satisfies a standard applicable to the modification that is recognized by, or contained in a regulation
or guidance issued by, the Secretary;
or
“(II) is made pursuant to methods or criteria approved or included in a premarket submission approved or cleared by the Secretary for the in vitro clinical test being modified;
“(ii) maintains any documentation required by the standard specified in clause (i)(I) or methodology or criteria specified in clause (i)(II); and
“(iii) submits to the Secretary on an annual basis a report summarizing each such modification to a high-risk in vitro clinical test.
“(B) SPECIMEN-RELATED MODIFICATIONS.—Notwithstanding paragraph (1), a premarket application or listing shall not be required to be submitted pursuant to subsection (e), (d), (e), or (f) with respect to a modification to an in vitro clinical test if the modification is a specimen-related modification—
“(i) made pursuant to methods or criteria approved or included in a premarket submission to the Secretary for the in vitro
93

clinical test being modified or methods,
standards, or criteria otherwise approved
or recognized by the Secretary;

“(ii) made solely for the purpose of
extending specimen stability; or

“(iii) otherwise subject to an excep-
tion from, or not described in, paragraph
(1).

“(5) NEW PLATFORMS AND IN VITRO CLINICAL
TEST REPLACEMENTS.—

“(A) IN GENERAL.—When an in vitro clin-
cical test has been approved, or is otherwise le-
gally marketed pursuant to this section for use
on a specific platform that has been approved,
legally marketed, or deemed approved under
this section within a platform family, a submis-
sion under subsection (c), (d), or (f) shall not
be required for application of that in vitro clin-
cical test to a new platform within that platform
family.

“(B) PLATFORM FAMILIES.—A platform is
in a platform family if the developer dem-
onstrates and documents internally that the
platform and platform family—
“(i) have the same basic design and performance characteristics;

“(ii) have the same intended use and function;

“(iii) share the same measurement principle; and

“(iv) produce a similar analytical result from samples of the same specimen type.

“(6) OFFERING ALLOWED.—

“(A) IN GENERAL.—In the case of a modification subject to the notification requirement under paragraph (3), notwithstanding paragraph (1), the developer of the in vitro clinical test involved may offer the test during the 30-day period beginning on the date on which the developer is notified of the Secretary’s receipt of the notice of such modification, which shall be no later than 5 days after actual receipt by the Secretary, unless the Secretary, within such 30-day period—

“(i) informs the developer in writing that the notice is not adequate to satisfy the standard in paragraph (3); and
“(ii) informs the developer of such further information or action that is required for acceptance of such modification under paragraph (3).

“(B) ACCEPTANCE.—If the Secretary does not take an action described in clause (i) or (ii) of subparagraph (A) with respect to a modification by the end of the 30-day period described in such subparagraph—

“(i) the Secretary shall be considered to have accepted the modification; and

“(ii) the developer may offer or continue to offer the in vitro clinical test.

“(C) REVIEW OF SUPPLEMENTAL APPLICATION.—The Secretary shall review any submission required to be submitted pursuant to clause (i) or (ii) of subparagraph (A) not later than 120 days after the receipt of the supplemental submission for a high-risk in vitro clinical test, or 75 days after the receipt of the supplemental submission for a moderate-risk in vitro clinical test. The number of days during which the Secretary reviews a notice of such modification shall be deducted from such 120-day or 75-day review period.
“(7) Determination on whether to make submission.—The entity that modifies an in vitro clinical test is the entity responsible for submitting such modification for any approval or listing required by paragraph (1) and for any related quality system requirements under section 590D.

“(8) Scope of review.—In reviewing a modification to an in vitro clinical test pursuant to this subsection, the Secretary shall limit the scope of the review to the modification and the effect of such modification and shall not conduct a de novo review of the overall test.

“(9) Definition of meaningful clinical impact.—In this subsection, the term ‘meaningful clinical impact’ means, with respect to a modification of an in vitro clinical test—

“(A) a modification that changes the diagnosis or therapy delivered to the patient;

“(B) a modification of, or an addition to, the indications for use of the test that—

“(i) introduce new risks not typically associated with the previous indications for use;
“(ii) impact public health to a significantly greater degree than the previous indications for use;

“(iii) are not supported by a body of evidence that reflects an understanding within the scientific or clinical community that the changed or additional indications for use are a subset of previous indications for use; or

“(iv) are such that performance characteristics or clinical endpoints established to evaluate the previous indications for use cannot be applied to the changed or additional indications for use;

“(C) a modification that causes a low-risk in vitro clinical test to no longer meet required mitigating measures established for such test, such that the modified test is classified as a moderate-risk or high-risk test;

“(D) a modification to a moderate-risk or high-risk in vitro clinical test if the risk assessment for the modification, prior to consideration of verification and validation and considering relevant existing mitigating measures, demonstrates that there is a meaningful and
not remote increase in risk to the patient or user for the intended uses, unless validation and verification demonstrate that there is not a meaningful increase in risk to the patient or user for the intended uses compared to the risk assessment for the test as previously approved; or

“(E) in the case of a modification to a moderate-risk or high-risk in vitro clinical test, a modification that, if, following verification and validation of the test, the in vitro clinical test no longer meets the analytical or clinical performance standards for the intended uses for which the test is approved.

“(o) LISTING REQUIREMENT.—

“(1) IN GENERAL.—The Secretary shall establish and maintain a list of all in vitro clinical tests approved or otherwise required to be listed under this subchapter.

“(2) PROCESS AND CONTENT OF LISTING.—

The list under paragraph (1) shall, with respect to each in vitro clinical test, include—

“(A) the name of the in vitro clinical test;

“(B) the name and contact information of the developer;
“(C) with respect to a laboratory test protocol transferred, licensed, or purchased under subsection (i), the name and contact information of any transferee, licensee, or purchaser and the completion date of such transfer, license, or purchase;

“(D) a statement of whether the in vitro clinical test is a laboratory test protocol or a finished product;

“(E) the intended use of the in vitro clinical test; and

“(F) the classification, if available, or a similar summary description of the in vitro clinical test.

“(3) PROCESS AND TIMING OF LISTING.—The developer of an in vitro clinical test that is approved or otherwise required to be listed under this subchapter shall list with the Secretary the information described in paragraph (2)—

“(A) in the case of an in vitro clinical test first offered on or after the date that is 180 calendar days after enactment of the Diagnostic Accuracy and Innovation Act, not later than 10 calendar days after the date on which such in vitro clinical test is first offered;
“(B) in the case of an in vitro clinical test that has been first offered before the date that is 180 calendar days after enactment of the Diagnostic Accuracy and Innovation Act, and which continues to be so offered, not later than 180 calendar days after the date of the enactment of such Act; and

“(C) in the case of a laboratory test protocol that is transferred, licensed, or sold under subsection (i), the later of—

“(i) 180 calendar days after enactment of the Diagnostic Accuracy and Innovation Act; or

“(ii) 10 calendar days after the date of completion of such transfer, license, or sale.

“(4) UPDATED LISTING.—The developer of an in vitro clinical test shall submit an updated listing under paragraph (3) on an annual basis.

“(p) REGISTRATION.—

“(1) INITIAL REGISTRATION.—Before the earlier of offering an in vitro clinical test or submitting an application for approval of such a test under this section, the developer of the test shall register with the Secretary and include in such registration—
“(A) the developer’s name;

“(B) the developer’s place of business; and

“(C) a list of the establishments at which
the developer is engaged in the design, develop-
ment, validation, production, manufacture,
preparation, propagation, or assembly of an in
vitro clinical test.

“(2) Establishments with grandfathered
in vitro clinical tests.—Notwithstanding para-
graph (1), the developer of an in vitro clinical test
described in subsection (l)(1) shall register with Sec-
retary and include in such registration the informa-
tion listed in paragraph (1) not later than 180 cal-
endar days after the date of enactment of the Diag-
nostic Accuracy and Innovation Act.

“(3) Additional establishments.—Every
developer of an in vitro clinical test required to be
registered under paragraph (1) or (2) shall register
with the Secretary any additional establishment at
which the developer begins the design, development,
validation, production, manufacture, preparation,
propagation, or assembly of an in vitro clinical test
not later than 30 calendar days after first engaging
in such activity.
“(4) ANNUAL UPDATES.—On or before December 31 of each year, every developer of an in vitro clinical test shall submit an updated registration under paragraph (1) or (2), as applicable.

“(5) INFORMATION CHANGES.—The developer of an in vitro clinical test shall notify the Secretary of any change to the registration information provided under this subsection not later than 30 calendar days after such change.

“(6) AFFILIATE REGISTRATION.—Registration information required to be submitted by a developer of an in vitro clinical test under this subsection may be submitted by a parent, subsidiary, or affiliate company with respect to any establishment under the joint ownership or control of the submitter and the developer.

“(7) REGULATIONS.—The Secretary shall, to the extent possible, harmonize regulations for carrying out this subsection with the corresponding regulations for registration with respect to devices.

“(q) LABELING.—Notwithstanding any provision of this Act—

“(1) an in vitro clinical test may be labeled by electronic means (including by directing health care practitioners and other users to information posted
on the Internet) instead of physically affixing the
information to the in vitro clinical test;

“(2) an in vitro clinical test need not be labeled
for purposes of transferring the test between entities
if—

“(A) the first entity controls or has the
power to control the other entity;

“(B) the other entity controls or has the
power to control the first entity; or

“(C) the two entities are under common
ownership or control of a third entity;

“(3) patient-specific test results from the use of
an in vitro clinical test or an interpretation of such
patient tests results shall not constitute labeling;

“(4) patient-specific scientific or clinical ex-
changes or discussion regarding one or more in vitro
clinical tests shall not constitute labeling;

“(5) the Secretary may require the developer of
a platform to receive approval from the Secretary
before making any claim regarding the clinical valid-
ity of the platform alone; and

“(6) in vitro clinical test labeling, advertising,
and promotion shall not be treated as misbranded or
adulterated by reason of—
“(A) the use of the terms in vitro diagnostic device or IVD in lieu of the terms in vitro clinical test or IVCT; and

“(B) the use of internationally harmonized symbols without accompanying text.

“SEC. 590C. INVESTIGATIONAL AND RESEARCH USE IN VITRO CLINICAL TESTS.

“(a) IN GENERAL.—Except as provided in subsection (b), an in vitro clinical test for investigational use shall be exempt from the requirements of this subchapter other than sections 590F, 590G, and 590H. Sections 502 and 721, made applicable to in vitro clinical tests by section 590H, shall not apply to such tests.

“(b) APPLICATION FOR AN EXEMPTION.—

“(1) IN GENERAL.—The Secretary shall establish a process under which—

“(A) the Secretary shall require that in the case of an in vitro clinical test the investigational use of which the Secretary determines poses a significant risk to the public health (other than with respect to an investigation for the collection of clinical data through processes other than a prospective clinical trial), a sponsor of an investigation of such a test seeking an exemption under subsection (a) submits to the
Secretary an investigational use application with respect to the test in accordance with paragraphs (2) and (3); and

“(B) in the case of an in vitro clinical test, the investigational use of which the Secretary does not determine poses such a risk—

“(i) the Secretary shall require that the sponsor of such investigation complies with—

“(I) the requirements specified in paragraphs (3)(A), (3)(B), and (5)(A)(iii); and

“(II) such other requirements as the Secretary may reasonably determine to be necessary for the protection of the public health and safety, including the monitoring of investigations conducted with such test, the establishment and maintenance of records, and the submission to the Secretary of reports of data obtained as a result of the investigational use of the in vitro clinical test during the period covered by the exemption; and
“(ii) the exemptions specified in paragraph (5)(B) and subsection (g) are available with respect to such test.

“(2) APPLICATION CONTENTS.—An investigational use application shall be submitted in such time and manner and contain such information as the Secretary may require, including assurances to the satisfaction of the Secretary that the sponsor involved shall, with respect to the in vitro clinical test that is the subject of the application—

“(A) establish and maintain any records relevant to such in vitro clinical test; and

“(B) submit to the Secretary reports of data obtained as a result of the investigational use of the in vitro clinical test during the period covered by the exemption that the Secretary reasonably determines will enable the Secretary—

“(i) to ensure compliance with the conditions for approval specified in paragraph (3);

“(ii) to review the progress of the investigation involved; and

“(iii) to evaluate the analytical validity and clinical validity of such test.
“(3) CONDITIONS OF APPROVAL.—An investiga-
tional use application shall only be approved if—

“(A) the proposed labeling for the in vitro
clinical test involved clearly and conspicuously
states ‘For investigational use’;

“(B) in the case of an application sub-
mitted with respect to an in vitro clinical test
the clinical testing of which involves human
subjects, the sponsor of the investigation—

“(i) if the Secretary has established
an institutional review committee to super-
vise clinical testing of such in vitro clinical
tests, submits—

“(I) to such committee a plan
that meets the requirements specified
in paragraph (5) for any proposed
clinical testing of the in vitro clinical
test and a report of prior investiga-
tions of the test adequate to justify
the proposed clinical testing; and

“(II) to the Secretary a summary
of such plan and a report of prior in-
vestigations; or

“(ii) if no such committee has been so
established or the Secretary finds that the
process of review by such a committee is inadequate (whether or not the plan for such testing has been approved by such committee), for purposes of beginning clinical testing of the test, submits to the Secretary a plan that meets the requirements specified in paragraph (5) for any proposed clinical testing of the in vitro clinical test and a report of prior investigations of the test adequate to justify the proposed clinical testing; and

“(C) the sponsor submitting such application provides assurances to the Secretary that the sponsor will comply with such other requirements as the Secretary may reasonably determine to be necessary for the protection of the public health and safety.

“(4) Coordination with investigational new drug applications.—Any requirement for the submission of a report to the Secretary pursuant to an investigational new drug application involving an in vitro clinical test shall supersede the reporting requirement in paragraph (2)(B), but only to the extent the requirement with respect to the investiga-
tional new drug application is duplicative of the reporting requirement under such paragraph.

“(5) INVESTIGATION PLAN REQUIREMENTS.—

“(A) IN GENERAL.—With respect to a plan submitted under paragraph (3)(B), the sponsor submitting such plan shall—

“(i) in the case of such a plan submitted to an institutional review committee, promptly notify the Secretary, under such circumstances and in such manner as the Secretary may prescribe, of the approval or the suspension or termination of the approval of such plan by an institutional review committee;

“(ii) in the case of an in vitro clinical test to be distributed or otherwise made available to investigators for clinical testing, obtain, and submit to the Secretary, signed agreements from each of the individuals carrying out the investigation that is the subject of such plan that—

“(I) any testing under such plan involving human subjects will be under the supervision of such individual; and
“(II) the individual will ensure that informed consent is obtained from each such human subject; and

“(iii) submit an assurance to the Secretary that informed consent will be obtained from each human subject (or the representative of such subject) of proposed clinical testing involving such in vitro clinical test, except in cases in which, subject to such other conditions as the Secretary may prescribe—

“(I) the proposed clinical testing poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of the human subject; or

“(II) the investigator conducting or supervising the proposed clinical testing determines (subject to subparagraph (B)(ii), with the concurrence of a licensed physician who is not involved in the testing of the human subject) in writing that—
“(aa) there exists a life-threatening situation involving
the human subject of such testing which necessitates the use of
such in vitro clinical test;

“(bb) it is not feasible to obtain informed consent from the
subject; and

“(cc) there is not sufficient time to obtain such consent from
his representative.

“(B) EXCEPTIONS.—

“(i) SIGNED AGREEMENTS NOT REQUIRED FOR AFFILIATES.—Subparagraph
(A)(iii) shall not apply to the distribution
of or other arrangements by a sponsor to make available an in vitro clinical test to an investigator that is employed by or affiiliated with the sponsor.

“(ii) CONCURRENCE OF PHYSICIAN NOT REQUIRED.—The requirement to obtain the concurrence of a licensed physician with respect to a determination under subparagraph (A)(iii)(II) shall not apply if—
“(I) immediate use of the in vitro clinical test in the investigation involved is required to save the life of the human subject; and

“(II) there is not sufficient time to obtain such concurrence.

“(iii) INFORMED CONSENT NOT REQUIRED WITH RESPECT TO CERTAIN SPECIMENS.—Notwithstanding subparagraph (A)(iii)(II), the informed consent of human subjects shall not be required to be obtained with respect to clinical testing conducted as part of an investigation, if—

“(I) the clinical testing uses remnants of specimens collected for routine clinical care or analysis that would have been discarded, leftover specimens that were previously collected for other research purposes, or specimens obtained from specimen repositories;

“(II) the identity of the subject of the specimen is not known to, and may not readily be ascertained by, the investigator or any other individual
associated with the investigation, including the sponsor;

“(III) any clinical information that accompanies the specimens does not make the specimen source identifiable to the investigator or any other individual associated with the investigation, including the sponsor;

“(IV) the individuals caring for the human subjects as patients are different from, and do not share information about the patient with, the individuals conducting the investigation; and

“(V) the specimens are provided to the investigators without personally identifiable information and the supplier of the specimens has established policies and procedures to prevent the release of personally identifiable information.

“(6) CLASSIFICATION.—If a developer seeks classification of an in vitro clinical test during its investigational use, the Secretary shall use processes
and classifications that are consistent with the processes and classifications under section 590A.

“(7) Variation of Requirements Allowed.—The requirements of this subsection with respect to an investigational use application may vary based on—

“(A) the scope and duration of clinical testing to be conducted under investigation that is the subject of such application;

“(B) the number of human subjects that are to be involved in such testing;

“(C) the need to permit changes to be made in the in vitro clinical test involved during testing conducted in accordance with a plan required under paragraph (3)(B); or

“(D) whether the clinical testing of such in vitro clinical test is for the purpose of developing data to obtain approval to offer such test.

“(c) Review of Applications.—

“(1) Failure to Act.—Unless the Secretary, not later than the date that is 30 calendar days after the date of the submission of an investigational use application that meets the requirements of subsection (b)(2), issues an order disapproving the application and notifies the sponsor submitting the ap-
lication of such disapproval, the application shall be
treated as approved as of such date without further
action by the Secretary.

“(2) DISAPPROVAL.—The Secretary may dis-
approve an investigational use application submitted
under this subsection only if the Secretary deter-
mines that the investigation with respect to which
the application is submitted does not conform to the
requirements of subsection (b)(3). A notification of
such disapproval submitted to the sponsor with re-
spect to such an application shall—

“(A) contain the order of disapproval and
a complete statement of the reasons for the
Secretary’s disapproval of the application; and

“(B) provide the sponsor with an oppor-
tunity for an informal hearing on the dis-
approval.

“(d) WITHDRAWAL OF APPROVAL.—

“(1) IN GENERAL.—The Secretary may, by ad-
ministrative order, withdraw the approval of an ex-
emption granted under this subsection with respect
to an in vitro clinical test if the Secretary deter-
dines that the test does not meet the applicable con-
ditions under subsection (b)(3) for such approval.

“(2) OPPORTUNITY TO BE HEARD.—
“(A) IN GENERAL.—Subject to subparagraph (B), an order withdrawing the approval of an exemption granted under this subsection may be issued after the Secretary provides the applicant or sponsor of the test with an opportunity for an informal hearing.

“(B) EXCEPTION.—An order referred to in subparagraph (A) with respect to an exemption granted under this subsection may be issued before the provision of an opportunity for an informal hearing if the Secretary determines that the continuation of testing under the exemption will result in an unreasonable risk to the public health.

“(e) CHANGES.—

“(1) IN GENERAL.—The Secretary shall by regulation establish, with respect to an in vitro clinical test for which an exemption under this subsection is in effect, procedures and conditions under which the changes to the test are allowed without the additional approval of an application for an exemption or the approval of a supplement to such an application. Such regulations shall provide that such a change may be made if—
“(A) the sponsor or applicant determines, on the basis of credible information (as defined by the Secretary) that the change meets the conditions specified in paragraph (2); and

“(B) the sponsor or applicant submits to the Secretary, not later than 5 calendar days after making the change, a notice of the change.

“(2) CONDITIONS.—The conditions specified in this paragraph are that—

“(A) in the case of developmental changes to an in vitro clinical test (including manufacturing changes), the changes—

“(i)(I) do not constitute a significant change in design or in basic principles of operation; or

“(II) do not constitute a significant increase in risk to patients; and

“(ii) are made in response to information gathered during the course of an investigation; and

“(B) in the case of changes to clinical protocols applicable to the test, the changes do not affect—
“(i) the validity of data or information resulting from the completion of an approved clinical protocol;

“(ii) the scientific soundness of a plan submitted under subsection (b)(3)(B); or

“(iii) the rights, safety, or welfare of the human subjects (if any) involved in the investigation.

“(f) PRESUBMISSION MEETING.—

“(1) IN GENERAL.—In the case of an applicant intending to investigate the analytical validity or clinical validity of a high- or moderate-risk in vitro clinical test, the Secretary shall ensure that the applicant has an opportunity, prior to submitting an application to the Secretary under subsection (b)(1), to submit to the Secretary for review an investigational plan (including a clinical protocol).

“(2) REQUEST FOR MEETING.—If the applicant described in paragraph (1) submits a written request for a meeting with the Secretary regarding the review of an investigational plan described in such paragraph, the Secretary shall, not later than 30 calendar days after receiving the request, meet with the applicant for the purpose of reaching agreement
regarding the investigational plan. The written request shall include—

“(A) a detailed description of the in vitro clinical test involved;

“(B) a detailed description of the proposed conditions of use of such test; and

“(C) a proposed plan (including a clinical protocol) for determining whether there is a reasonable assurance of clinical validity or probable clinical validity (as applicable) of, and, if available, information regarding the expected performance from, such test.

“(3) AGREEMENT.—

“(A) REDUCED TO WRITING.—Any agreement under this subsection between the Secretary and an applicant described in paragraph (1) shall be in writing and part of the administrative record.

“(B) NO AMENDMENTS.—An agreement described in paragraph (1) shall not be changed except—

“(i) with the written agreement of the applicant described in such paragraph; or

“(ii) pursuant to a decision, made in accordance with subparagraph (C) by the
director of the center involved in the re-
view, that a substantial scientific issue es-
sential to determining the clinical validity
of the in vitro clinical test involved has
been identified.

“(C) Decision by Director.—A decision
referred to in subparagraph (B)(ii) shall be in
writing, and may be made only after the Sec-
retary has provided to the applicant described
in paragraph (1) an opportunity for a meeting
at which the director and such applicant are
present and at which the director documents
the scientific issue involved, the decision, and
the rationale for the decision.

“(g) Exemption From Human Subject Regu-
lations.—An investigation conducted under an exemption
under this section with respect to an in vitro clinical test
that involves the collection or study of existing data, docu-
ments, records, pathological specimens, or diagnostic
specimens, is exempt from the rules in part 50 of title
21, Code of Federal Regulations (or any successor regu-
lations), if the information obtained during such investiga-
tion is recorded by the investigator in such a manner that
the subjects cannot be identified, directly or through per-
sonally identifiable information linked to the subjects.
“(h) CLINICAL HOLD.—

“(1) IN GENERAL.—At any time, the Secretary may impose a clinical hold with respect to an investigation of an in vitro clinical test if the Secretary makes a determination described in paragraph (2). The Secretary shall, in imposing such clinical hold, specify the basis for the clinical hold, including the specific information available to the Secretary which served as the basis for such clinical hold, and confirm such determination in writing. The applicant or sponsor may immediately appeal any such determination pursuant to section 590F.

“(2) DETERMINATION.—For purposes of paragraph (1), a determination described in this subparagraph with respect to a clinical hold is a determination that—

“(A) based on credible evidence, the in vitro clinical test involved presents an unreasonable risk to the safety of the persons who are the subjects of the investigation, taking into account the qualifications of the investigators, information about the in vitro clinical test, the design of the investigation, the condition for which the in vitro clinical test is to be inves-
tigated, and the health status of the subjects involved; or

“(B) based on credible evidence, investigator misconduct or applicant or sponsor non-compliance with the requirements of this section present an unreasonable risk to the safety of the persons who are the subjects of the clinical investigation.

“(3) APPEAL.—An applicant or sponsor of an investigation may submit to the Secretary a written request that a clinical hold imposed under this subsection be removed. Any such request shall include sufficient information to support the removal of such clinical hold. Not later than 30 calendar days after receipt of such request, the Secretary shall respond to such a request, in writing and, if denying such request, specify the reasons for such denial.

“(i) DEFINITIONS.—In this section:

“(1) The term ‘affiliated’ means, with respect to an applicant or sponsor, owning the applicant or sponsor, owned by the applicant or sponsor, under common ownership with the applicant or sponsor, or in a joint venture with the applicant or sponsor.

“(2) The term ‘clinical hold’ means an action taken by the Secretary prohibiting the applicant or
sponsor of an investigation of an in vitro clinical test
from conducting the investigation.

“(3) The term ‘invasive sampling procedure’,
does not include venipuncture or other minimally
invasive sampling procedures, or the use of surplus
samples of body fluids or tissues that remain from
samples previously taken.

“(4) The term ‘investigational use application’
means, with respect to an in vitro clinical test, an
application submitted under subsection (b)(1)(A) for
the use of the test by experts qualified by scientific
training and experience to investigate the analytical
validity and clinical validity of the test.

“(5) The term ‘serious or life-threatening dis-
ease or condition’ means a disease or condition—

“(A) for which the likelihood of death
within one year is high unless the course of the
disease or condition is interrupted;

“(B) that results in permanent impairment
of a bodily function or permanent damage to a
bodily structure within one year unless the
course of the disease or condition is inter-
rupted; or

“(C) that necessitates medical or surgical
intervention within one year to preclude perma-
(6) The term ‘significant risk’ means, with respect to an in vitro clinical test that is the subject of an investigational use application, that the investigational use of the test—

(A) is a use of substantial importance in identifying, measuring, detecting, predicting, monitoring, or assisting in selecting treatment for, a serious or life-threatening disease or condition without confirmation of the diagnosis by a medically established means;

(B) requires an invasive sampling procedure; or

(C) otherwise presents a reasonably foreseeable serious risk to the health of a human subject.

(j) Exception for Tests Used Only in Research.—

(1) Research-use-only tests.—

(A) In general.—Except as provided in subparagraph (B), research-use-only in vitro clinical tests shall not be subject to the requirements of this Act.
“(B) LABELING.—The Secretary shall require that any research-use-only in vitro clinical test be labeled for research use only.

“(2) BASIC RESEARCH TESTS.—Basic research tests shall not be subject to regulation under this Act.

“(3) DEFINITIONS.—In this subsection:

“(A) RESEARCH-USE-ONLY IN VITRO CLINICAL TEST.—The term ‘research-use-only in vitro clinical test’ means an in vitro clinical test that is intended by the developer for use solely in the laboratory phase of development and the results of which are not intended for use in patient care. Such term does not include an in vitro clinical test intended for investigational use subject to subsection (a) or (b).

“(B) BASIC RESEARCH TEST.—The term ‘basic research test’ means a test that—

“(i) is intended by the developer solely for use in the conduct of nonclinical laboratory research, and not for the development of an in vitro clinical test; and

“(ii) is not an in vitro clinical test.
SEC. 590D. QUALITY REQUIREMENTS; UNIQUE IDENTIFIERS.

(a) In general.—The Secretary shall establish, by regulation, quality requirements for the development and production of in vitro clinical tests offered under this subchapter. In establishing such requirements, the Secretary shall consider whether to include requirements for each of the following:

(1) Management responsibility.
(2) Quality audit.
(3) Personnel.
(4) Design controls.
(5) Document controls.
(6) Purchasing controls.
(7) Identification.
(8) Production and process controls.
(9) Acceptance activities.
(10) Nonconforming products.
(11) Corrective and preventive action.
(12) Labeling and package controls.
(13) Handling, storage, distribution, and installation.
(14) Records.
(15) Servicing.
(16) Statistical techniques.
“(b) Scope.—The quality requirements under this section shall—

“(1) apply only with respect to the design, development, validation, production, manufacture, preparation, propagation, or assembly of an in vitro clinical test, offered under this subchapter;

“(2) account for differences between in vitro clinical tests that are finished products and in vitro clinical tests that are laboratory test protocols;

“(3) not apply with respect to laboratory operations; and

“(4) not apply to components or parts of an in vitro clinical test or raw materials used in an in vitro clinical test.

“(c) Unique Identifiers.—

“(1) In general.—The Secretary shall promulgate regulations establishing a unique identification system for finished products requiring the label of finished products to bear a unique identifier, unless the Secretary requires an alternative placement or provides an exception for a particular finished product.

“(2) Requirements.—The unique identifier shall adequately identify the finished product through distribution and use, and may include infor-
The Secretary shall, to the extent possible, harmonize the unique identification system for finished products with, and use tools and systems developed by the Secretary for, the unique device identification system established by the Secretary pursuant to section 519(f). A unique identifier shall not be required for a laboratory test protocol.

“SEC. 590E. POSTMARKET REQUIREMENTS.

“(a) ADVERSE EVENT REPORTING.—

“(1) IN GENERAL.—The developer of any in vitro clinical test approved or listed under section 590B shall—

“(A) maintain records of any adverse event that is associated with the test and is known by the developer;

“(B) include in such records any information, or references to such information, that is in the developer’s possession and relates to the adverse event, including documentation of the developer’s deliberations used to determine whether an in vitro clinical test error is required to be reported under subparagraph (C) or (E);
“(C) submit to the Secretary a report on an adverse event—

“(i) not later than 5 calendar days after the adverse event becomes known to the developer, if the adverse event involves a patient death; or

“(ii) not later than 15 calendar days after the adverse event becomes known to the developer, if the adverse event presents an imminent threat to public health;

“(D) include in any report under clause (i) or (ii) of subparagraph (C), as applicable and available, information regarding—

“(i) the patient;

“(ii) the in vitro clinical test;

“(iii) the adverse event;

“(iv) the person who reported the adverse event to the developer;

“(v) the developer; and

“(vi) the laboratory;

“(E) not later than 30 calendar days after the end of a calendar quarter, submit to the Secretary a report on any adverse events that are associated with the test and become known
to the developer during the preceding quarter of
the year, if any; and

“(F) include in any report under subparagraph (E)—

“(i) the number and type of such adverse events which became known to the
developer during the quarter covered by the report, identifying any new types of adverse events;

“(ii) trend information for a statistically meaningful sample period regarding adverse events that are associated with the test; and

“(iii) aggregated summary information regarding the medical impact of such adverse events on patients, if known.

“(2) LIMITATION ON SECRETARY’S AUTHORITY
TO REQUIRE ADDITIONAL INFORMATION.—With re-
spect to a report submitted under paragraph (1)(E), the Secretary may not require that such report in-
clude any information other than the information specified in clauses (i), (ii), and (iii) of paragraph
(1)(F).

“(3) STATEMENT REQUIRED IN LIEU OF INFOR-
MATION IN CERTAIN QUARTERS.—A report under
paragraph (1)(E) for any quarter in which no adverse events occur shall be limited to a statement, to the knowledge of the developer, that no reportable adverse events occurred in such quarter.

“(4) LABORATORY ERRORS.—The developer of an in vitro clinical test shall not be required to maintain records or report under this section regarding laboratory errors that are subject to section 353(f)(5) of the Public Health Service Act and corrective and preventive actions to address such errors.

“(5) REPORT NOT AN ADMISSION.—A report or other information submitted by a developer or other responsible party under this subsection (and any release by the Secretary of that report or other information) does not constitute an admission by the developer or other responsible party that, and shall not be discoverable or admissible in a court of law as evidence that, the in vitro clinical test caused or contributed to an adverse event.

“(6) REQUESTS FOR ALTERNATIVE PROCESS.—The Secretary may establish by regulation and implement a program under which—

“(A) in vitro clinical test developers may request a process for reporting adverse events
other than the processes set forth in this subsection; and

“(B) the Secretary grants or denies any such request by order, notwithstanding sub-
chapter II of chapter 5 of title 5, United States Code.

“(7) DEFINITIONS.—In this subsection:

“(A) The term ‘adverse event’ means—

“(i) any death or serious injury that is reasonably believed to have been caused by an in vitro clinical test error; or

“(ii) any in vitro clinical test error which is more likely than not to reoccur and, if the error were to reoccur, would have a reasonable probability of causing death or serious injury.

“(B) The term ‘caused by an in vitro clinical test error’ means that an in vitro clinical test error was the primary factor in the death of, or serious injury to, a specific patient or user.

“(C) The term ‘in vitro clinical test error’ means a clinically significant failure of an in vitro clinical test to meet its performance specifications or otherwise perform as intended, ex-
cept that such term excludes any such event or error related to laboratory operations.

“(D) The term ‘permanent’ means irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage.

“(E) The term ‘serious injury’ means an injury or illness that—

“(i) is life-threatening;

“(ii) results in permanent impairment of a body function or permanent damage to a body structure; or

“(iii) necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.

“(b) NOTIFICATION.—

“(1) IN GENERAL.—Except with respect to an in vitro clinical test described in section 590B(l)(4), the Secretary may issue such notifications or orders as may be necessary to assure that adequate notification is provided in an appropriate form, by the persons and means best suited under the circumstances involved, to all health care practitioners who prescribe or use an in vitro clinical test and to
any other person (including manufacturers, import-
ers, distributors, retailers, and users (including
home users)) who should properly receive such noti-
ification, if the Secretary determines that—

“(A) the in vitro clinical test presents an
unreasonable risk of substantial harm to the
public health when used as intended; and

“(B) notification under this subsection is
necessary to eliminate or reduce the unreason-
able risk of such harm and no more practicable
means is available under the provisions of this
Act (other than this section) to eliminate or re-
duce such risk.

“(2) ORDERS.—An order under this subsection
shall require that the individuals subject to the risk
with respect to which the order is to be issued be in-
cluded in the persons to be notified of the risk un-
less the Secretary determines that notice to such in-
dividuals would present a greater danger to the
health of such individuals than no such notification.
That notification shall describe the risk presented by
the test and any action which may be taken to elimi-
nate or reduce such risk. Before issuing an order
under this subsection, the Secretary shall consult
with the persons who are to give notice under the order.

“(c) VOLUNTARY CORRECTIONS AND REMOVALS.—

“(1) IN GENERAL.—A developer or other responsible party may, at any time, initiate a voluntary correction or removal action with respect to an in vitro clinical test.

“(2) NOTICE TO SECRETARY.—Not later than 7 calendar days after the first correction or removal action undertaken by the developer or other responsible party pursuant to paragraph (1), to reduce a risk to health posed by an in vitro clinical test that is in violation of this subchapter, the developer or other responsible party shall submit to the Secretary, as applicable and reasonably necessary—

“(A) the name, unique identifier, and other similar information about the in vitro clinical test;

“(B) the name, address, contact information, and registration number of the developer or other responsible party;

“(C) a copy of any customer notification issued by the developer or other responsible party;
“(D) a description of the problem sought to be addressed by the correction or removal, including a health hazard evaluation;

“(E) a status and summary of the developer or other responsible party’s internal investigation;

“(F) the number of adverse event reports related to the problem sought to be addressed by the correction or removal;

“(G) relevant in vitro clinical test labeling, including instructions for use; and

“(H) a list of consignees.

“(3) Correction or removal identifier.—Not later than 7 calendar days after receipt of a notification under paragraph (2), the Secretary shall assign a unique correction or removal identifier to such action and provide such identifier to the developer or other responsible party. The developer, Secretary, or other responsible party shall include such unique identifier on all subsequent correspondence regarding the correction or removal action with the Secretary, developer, health care practitioner, or any user.

“(4) Notice to users.—If communication of a correction or removal action is necessary to protect
public health, such communication shall include, as applicable and reasonably available—

“(A) the unique correction or removal identifier, as assigned by the Secretary;

“(B) information sufficient to identify the in vitro clinical test subject to the correction or removal;

“(C) a description of the problem sought to be addressed by the correction or removal, including the extent of the problem;

“(D) a description of the potential risks to patients or the public due to the problem, including whether injuries or deaths have been associated with the problem;

“(E) instructions to the patient, health care practitioner, or other user, on appropriate actions to be taken; and

“(F) contact information for obtaining additional information from the developer or other responsible party.

“(5) CLASSIFICATION OF CORRECTION OR REMOVAL.—The Secretary shall classify a correction or removal under this subsection (according to the relative degree of health hazard presented by the in vitro clinical test being corrected or removed) within
30 calendar days of receiving notice pursuant to paragraph (2). If the Secretary determines a notification of such classification in addition to any notification already provided by the developer or other responsible party pursuant to paragraph (4) is necessary to protect public health, the Secretary may issue such notice, and shall include in such notice the unique correction or removal identifier and information clarifying that such notice is intended to inform patients, health care practitioners, and other users that the notice is not a second correction or removal and that the notice is part of an agency process for classifying an existing correction or removal.

“(6) REPORT NOT AN ADMISSION.—A report or other information submitted by a developer or other responsible party under this subsection (and any release by the Secretary of that report or other information) does not constitute an admission by the developer or other responsible party that the in vitro clinical test is in violation of this subchapter or caused or contributed to any injury.

“(7) CLOSING A CORRECTION OR REMOVAL.—Not later than 45 calendar days after the developer or other responsible party notifies the Secretary that
it has completed a correction or removal action, the Secretary shall provide the developer or other responsible party a written statement closing the correction or removal action or stating the reasons the Secretary cannot close the correction or removal action at that time.

“(d) MANDATORY CORRECTIONS AND REMOVALS.—

“(1) IN GENERAL.—If the Secretary finds there is a reasonable probability that an in vitro clinical test, when used in accordance with its intended use, would cause serious, adverse health consequences or death, and the Secretary finds that notification under this subsection is necessary to eliminate the unreasonable risk of such harm and no more practical means is available under this Act (other than this subsection) to eliminate such risk, then the Secretary shall issue an order requiring the appropriate person, as applicable, to promptly—

“(A) cease offering such test; and

“(B) notify health care practitioners and other users of the test of the order and recommend to such practitioners and users to cease offering or using such test; or

“(C) initiate a correction or removal of such test.
“(2) INFORMAL HEARING.—An order under paragraph (1) shall provide the person subject to the order with an opportunity for an informal hearing, to be held not later than 10 calendar days after the date of the issuance of the order, on the actions required by the order and on whether the order should be revised or vacated. If, after providing an opportunity for such a hearing, the Secretary determines that inadequate grounds exist to support the actions required by the order, the Secretary shall revise or vacate the order.

“(3) AMENDMENT TO REQUIRE CORRECTION OR REMOVAL.—

“(A) AMENDMENT.—If, after providing an opportunity for an informal hearing under paragraph (2), the Secretary determines that an order should be amended to include a correction or removal of the in vitro clinical test with respect to which the order was issued, the Secretary shall, except as provided in subparagraphs (B) and (C), amend the order to require a correction or removal. The Secretary shall specify a timetable in which the in vitro clinical test correction or removal will occur and shall require periodic reports to the Secretary de-
scribing the progress of the correction or removal.

“(B) CONTENTS.—An original or amended order under paragraph (1)—

“(i) shall—

“(I) not include correction or removal of an in vitro clinical test from individuals; and

“(II) not include correction or removal of an in vitro clinical test from any setting if the Secretary determines that the risk of correcting or removing such in vitro clinical test from the facilities presents a greater health risk than the health risk of not correcting or removing the in vitro clinical test from use; and

“(ii) may provide for notice to individuals subject to the risks associated with the use of such in vitro clinical test.

“(C) ASSISTANCE OF HEALTH CARE PRACTITIONERS.—In providing the notice required by subparagraph (B)(ii), the Secretary may use the assistance of health care practitioners who prescribed, ordered, or used such an in vitro
clinical test for individuals. If a significant number of such individuals cannot be identified, the Secretary shall notify such individuals pursuant to section 705(b).

“(4) CLASSIFICATION.—The Secretary shall classify a correction or removal under this subsection (according to the relative degree of health hazard presented by the in vitro clinical test being corrected or removed) within 30 calendar days of ordering the correction or removal.

“(e) INAPPLICABILITY TO CERTAIN MATTERS.—

“(1) IN GENERAL.—The Secretary shall not order a notification under subsection (b) or a correction or removal under subsection (d) on the basis of any of the following:

“(A) Changes or improvements in laboratory operations.

“(B) Corrections or updates to patient-specific laboratory reports.

“(C) Enhancements to an in vitro clinical test.

“(2) ENHANCEMENT.—For purposes of this subsection, the term ‘enhancement’ means a change to an in vitro clinical test that is not a change to
remedy a violation of this subchapter or associated regulations enforced by the Secretary.

“(f) Postmarket Surveillance.—

“(1) In general.—The Secretary may by order, at the time of approval of an in vitro clinical test pursuant to subsection (c), (d), or (f)(1)(A) of section 590B require a developer to conduct postmarket surveillance, including postmarket studies, for a high-risk in vitro clinical test, or a moderate-risk in vitro clinical test described in section 590A(a)(3)(A), only if the Secretary determines, based on valid scientific evidence, that the failure of such in vitro clinical test would be reasonably likely to have serious adverse health consequences. The Secretary shall not, under this subsection, order postmarket surveillance for an in vitro clinical test to assess clinical utility.

“(2) Surveillance approval.—Unless a different time period is agreed to by the developer and the Secretary, each developer required to conduct a surveillance of an in vitro clinical test shall, within 30 days of receiving an order from the Secretary prescribing that the developer is required under this subsection to conduct such surveillance, submit, for the approval of the Secretary, a plan for the re-
quired surveillance. The Secretary shall determine if
the person designated to conduct the surveillance
has appropriate qualifications and experience to un-
dertake such surveillance and if the plan will result
in the collection of useful data that can reveal un-
foreseen adverse events or other information nec-
essary to protect the public health. The developer
shall commence surveillance under this subsection
not later than 15 months after the day on which the
Secretary issues an order under this section. Any
such surveillance shall be completed within 3 years
of commencement.

“(3) POSTMARKET CLINICAL STUDIES.—The
Secretary may require the developer of an in vitro
clinical test to conduct a postmarket clinical study
under paragraph (1) only for a high-risk in vitro
clinical test and only if the Secretary determines
that no other means can provide the necessary infor-
mation. The authority to require such a study shall
not be delegated to any official or employee below
the level of senior management of the Center for In
vitro Clinical Tests.

“(g) MISBRANDED IN VITRO CLINICAL TESTS.—The
Secretary shall treat an in vitro clinical test as misbranded
under section 502 if the Secretary finds, based on all avail-
able data and information, that the in vitro clinical test
presents an unreasonable and substantial risk of illness
or injury when used as intended by its developer.

"SEC. 590F. APPEALS.

“(a) IN GENERAL.—The Secretary shall establish by
regulation an appeals process for the review of classifica-
tion and reclassification determinations under section
590A, premarket determinations under sections 590B and
590C, and other adverse decisions made by the Secretary
under this subchapter. Except as otherwise provided in
this subchapter, the process established by the Secretary
shall be consistent with the guidance entitled ‘Center for
Devices and Radiological Health Appeals Processes’ and
dated May 17, 2013.

“(b) TIMING FOR CERTAIN APPEALS.—With respect
to a premarket determination approving or disapproving
an application under section 590B, the applicant involved
or any interested person may, by petition filed on or before
the day that is 30 days after the date on which the Sec-
retary issues the order approving or disapproving such ap-
lication, obtain review of such determination under the
appeals process established pursuant to subsection (a).

“(c) FINAL ACTION FOR JUDICIAL REVIEW.—In all
cases, the process established under subsection (a) shall
provide for a decision constituting final action by the agen-
cy not later than 180 calendar days after the date on
which the appeal is first submitted.

“(d) ADVISORY PANELS.—The appeal process estab-
lished under subsection (a) shall permit the appellant to
request review by an advisory panel. Any such advisory
panel shall include persons with knowledge of in vitro clin-
ical tests, laboratory operations, and the use of in vitro
clinical tests.

“SEC. 590G. PREEMPTION.

“(a) IN GENERAL.—No State, tribal, or local govern-
ment (or political subdivision thereof) may establish or
continue in effect any requirement related to the develop-
ment, manufacture, labeling, distribution, sale, or use of
an in vitro clinical test that is different from, or in addi-
tion to, the requirements of this subchapter.

“(b) EXCEPTIONS.—Subsection (a) shall not be con-
strued to affect the authority of a State, tribal, or local
government—

“(1) to license laboratory personnel, health care
practitioners, or health care facilities or to regulate
any aspect of a health care practitioner-patient rela-
tionship; or

“(2) to enforce laws of general applicability,
such as zoning laws, environmental laws, labor laws,
and general business laws.
“(c) CLARIFICATION.—This section shall not be construed to shift liability to health care practitioners or other users.

“SEC. 590H. APPLICABILITY OF CERTAIN PROVISIONS.

“The provisions of sections 301, 303(f)(1), 304, 306, 501, 502, 503(a), 503(g), 506, 509, 517 , 520(e), 561, 562, 563, 566(b), 566(e), 702, 703, 704, 705, 721, 756, 770, 801, 802, 803, 1003, 1003a, and 1011 apply with respect to in vitro clinical tests to the same extent and in the same manner as such provisions apply with respect to devices, to the extent consistent with this subchapter, except as follows:

“(1) The following provisions do not apply with respect to in vitro clinical tests: Section 301(y), subsections (e), (f), (g), (h), and (i) of section 501, subsections (s), (t)(2), and (t)(3) of section 502, and section 510.

“(2) In the case of in vitro clinical tests, the statement required by section 502(v) is ‘‘Reprocessed in vitro clinical test for single use. Reprocessed by ____.’’

“(3) In applying section 503(g)(1)(B), if the Secretary determines that the primary mode of action is that of an in vitro clinical test, the agency
center charged with premarket review of in vitro
clinical tests shall have primary jurisdiction.”.

(b) CONFORMING AMENDMENT.—Section 517(a) of
360g(a)) is amended—

(1) by striking “or” at the end of paragraph
(8);

(2) by inserting “or” at the end of paragraph
(9); and

(3) by inserting after paragraph (9) the fol-
lowing:

“(10) the issuance of a decision under section
590F,”.

c) EMERGENCY USE OF IN VITRO CLINICAL
TESTS.—Section 564 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360bbb–3) is amended—

(1) in subsections (a)(1) and (a)(4)(C), by in-
serting “in vitro clinical test,” before “or biological
product” each place it appears;

(2) in paragraph (2) of subsection (b), by add-
ing at the end the following:

“(C) CONTINUED PRODUCT AVAILABILITY
AFTER TERMINATION.—A manufacturer or pro-
vider of an in vitro clinical test with an author-
ization under this section may consult with the
Secretary for, and the Secretary may allow, continued distribution and use of such test after termination of the authorization if the conditions of subsections (c)(2), (c)(3), and (c)(4) continue to be satisfied.”;

(3) in subsection (c), in the matter before paragraph (1), by inserting “(and with respect to in vitro clinical tests local, State, or regional public health authorities)” after “the Director of the Centers for Disease Control and Prevention”;

(4) in subsection (e)(3)—

(A) in subparagraph (A), by inserting “design (with respect to in vitro clinical tests),” before “manufacture,”; and

(B) in subparagraph (B), by striking “and” at the end;

(C) in subparagraph (C), by striking the period at the end and inserting “; and”; and

(D) by adding at the end the following:

“(D) quality system requirements (with respect to laboratories and laboratory operations) established under section 353 of the Public Health Service Act.”;
(5) in subsection (f)(2), by inserting “or, in the case of an in vitro clinical test, for diagnosis, prognosis, or monitoring” before “to the extent”; and

(6) in subsection (m)—

(A) in the subsection heading, by striking “LABORATORY TESTS ASSOCIATED WITH DEVICES” and inserting “IN VITRO CLINICAL TESTS”; and

(B) in paragraph (1)—

(i) by striking “a device” and inserting “an in vitro clinical test”; and

(ii) by striking “such device” and inserting “such in vitro clinical test”.

(d) INSPECTIONS.—Section 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374) is amended by adding at the end the following:

“(h) INSPECTIONS BY ACCREDITED PERSONS.—

“(1) IN GENERAL.—The Secretary shall establish by regulation a process to accredit persons for the purpose of conducting inspections of establishments engaged in the design, development, validation, production, manufacture, preparation, propagation, or assembly of an in vitro clinical test. The process established by the Secretary shall permit the owner or operator of such an establishment to select,
from the list published under paragraph (4), an accredited person to conduct such inspections.

“(2) ACCREDITATION CRITERIA.—The Secretary shall publish in the Federal Register criteria to accredit or deny accreditation to persons who request to perform the duties specified in paragraph (1).

“(3) DISPOSITION OF REQUESTS FOR ACCREDITATION.—The Secretary shall—

“(A) not later than 60 calendar days after the receipt of a request for accreditation under this subsection, inform the requesting person whether the request is adequate for review; and

“(B) promptly accredit or deny accreditation to the person.

“(4) LIST.—The Secretary shall—

“(A) publish on the Internet site of the Food and Drug Administration a list of persons who are accredited under this subsection; and

“(B) keep such list updated to ensure that the identity of each accredited person, and the particular activities for which the person is accredited, is available to the public.”.

(c) REGULATIONS.—
(1) PROMULGATION.—Not later than 3 years after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall promulgate final regulations to carry out the amendments made by this section.

(2) EFFECTIVE DATE.—

(A) IN GENERAL.—The regulations promulgated pursuant to paragraph (1) shall take effect on the date that is 2 years after the date of such promulgation.

(B) PREMARKET REQUIREMENTS.—Notwithstanding subparagraph (A), with respect to a manufacturer (as defined in section 7), the regulations promulgated pursuant to paragraph (1) to carry out sections 590A, 590B, and 590C of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), shall take effect on the date that is 1 year after the date of such promulgation.

(3) FINISHED PRODUCTS AND LABORATORY TEST PROTOCOLS.—All regulations established pursuant to paragraph (1) shall account for differences between finished products and laboratory test protocols (as such terms are defined in section 201(ss) of
the Federal Food, Drug, and Cosmetic Act, as added by section 2(a)).

(f) **Least Onerous and Most Efficient Implementation.**—Any regulations promulgated for purposes of implementation of subchapter J of chapter V of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)), any guidances or other similar documents expressly authorized or required under such subchapter, and any decision of the Secretary applying or implementing the requirements of such subchapter shall be developed and implemented in a manner that allows the regulated person to satisfy the regulated person’s relevant statutory obligations in the least onerous and most efficient manner possible. Any such regulation, guidance, or similar document shall set forth the manner in which the Secretary has complied with this subsection.

(g) **Education and Training of Agency Employees and Contractors.**—

(1) **Establishment of Plan.**—The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall—

(A) publish a proposed plan for education and training of employees and contractors of the Food and Drug Administration and the reg-
ulated community on implementation of the amendments made by this section;

(B) provide an opportunity for public comment on such plan during a period of not less than 90 calendar days;

(C) not later than 2 years after the date of enactment of this Act, publish a final version of such plan;

(D) ensure that initial training of employees and contractors under the plan is completed within 1 year of the date of publishing such final version; and

(E) offer training to the regulated community as described in the plan on an ongoing basis, beginning within 1 year of the date of publishing such final version.

(2) Plan Contents.—The plan required by paragraph (1) shall include—

(A) detailed plans for rigorous ongoing and initial training of employees and contractors of the Food and Drug Administration and the regulated community on implementation of the amendments made by this section, including the obligations for registration and listing, the standard for review and, approval of an in vitro
clinical test, and the contents of a submission
for approval of an in vitro clinical test under
section 590B of the Federal Food, Drug, and
Cosmetic Act, as added by subsection (a);

(B) education of such employees and con-
tractors on the operation of clinical laboratories
and the scope of activities within such labora-
tories that are subject to regulation under such
amendments; and

(C) ongoing training of such employees
and contractors on the technology and utiliza-
tion of in vitro clinical tests.

(h) ANNUAL REPORT.—Not later than one year after
the date of enactment of this Act, and annually thereafter,
the Secretary of Health and Human Services, acting
through the Commissioner of Food and Drugs, shall sub-
mit a report to the Congress—

(1) describing activities that have been under-
taken by the Food and Drug Administration pursu-
ant to the amendments made by this section and
progress toward relevant statutory deadlines;

(2) explaining the ways in which such activities
account for the unique characteristics of in vitro
clinical tests and differ from the regulation of de-
vices; and
(3) explaining the ways in which such activities promote patient access to new in vitro clinical tests.

(i) EXECUTIVE PERFORMANCE.—Timely and appropriate implementation and execution of this Act shall be included in the performance evaluations of relevant Food and Drug Administration executives, including members of the Senior Executive Service and equivalent positions, for purposes of determining any performance bonus, salary increase, or job advancement.

SEC. 4. FDA FEES.

(a) DEVELOPMENT OF USER FEES FOR IN VITRO CLINICAL TESTS.—

(1) IN GENERAL.—Beginning not later than October 1, 2018, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall develop recommendations to present to Congress with respect to the goals, and plans for meeting the goals, for the process for the review of in vitro clinical test applications submitted under subsections (e), (d), and (f) of section 590B of the Federal Food, Drug, and Cosmetic Act (as added by section 3 of this Act) for the first 7 fiscal years after fiscal year 2020. In developing such recommendations, the Secretary shall consult with—
(A) the Committee on Energy and Commerce of the House of Representatives;

(B) the Committee on Health, Education, Labor, and Pensions of the Senate;

(C) scientific and academic experts;

(D) health care professionals;

(E) representatives of patient and consumer advocacy groups; and

(F) the regulated industry.

(2) PUBLIC REVIEW OF RECOMMENDATIONS.—

After negotiations with the regulated industry, the Secretary shall—

(A) present the recommendations developed under paragraph (1) to the congressional committees specified in subparagraphs (A) and (B) of such paragraph;

(B) publish such recommendations in the Federal Register;

(C) provide for a period of not less than 30 days for the public to provide written comments on such recommendations;

(D) hold a meeting at which the public may present its views on such recommendations; and
(E) after consideration of such public views and comments, revise such recommendations as necessary.

(3) TRANSMITTAL OF RECOMMENDATIONS.—Not later than June 1, 2019, the Secretary shall transmit to Congress—

(A) the recommendations described in paragraph (1) (as revised under paragraph (2)(E));

(B) a summary of the views and comments received under paragraph (2), and any changes made to the recommendations in response to such views and comments.

(b) SENSE OF CONGRESS ON ESTABLISHMENT OF USER FEE PROGRAM.—It is the sense of the Congress that, based on the recommendations transmitted to Congress by the Secretary pursuant to subsection (a)(3), Congress should authorize a program, effective on the effective date of final regulations issued under section 3(e)(2)(B) of the Diagnostic Accuracy and Innovation Act, for the collection of user fees relating to the submission of applications for the approval of in vitro clinical tests under subsections (c), (d), and (f) of section 590B of the Federal Food, Drug, and Cosmetic Act (as added by section 3 of this Act).
(c) Transitional Provisions for User Fees for Certain In Vitro Clinical Tests.—A submission for approval or clearance of an in vitro clinical test (as defined in section 590 of the Federal Food, Drug, and Cosmetic Act (as added by section 3 of this Act)) made by a manufacturer of such test pursuant to section 6(c)(1)(A) of the Diagnostic Accuracy and Innovation Act shall be subject to a user fee pursuant to section 738 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j) in the same manner and to the same extent as a submission of a premarket application, premarket report, supplement, premarket notification submission, 30-day notice, request for classification information, or periodic reporting concerning a class III device is subject to such a user fee.

(d) Audit.—

(1) In General.—Beginning on the date that is 2 years after the date on which the Secretary of Health and Human Services receives the first user fee applicable to a submission of an application submitted with respect to an in vitro clinical test (as defined in section 590 of the Federal Food, Drug, and Cosmetic Act (as added by section 3 of this Act)) under subsection (c), (d), or (f) of section 590B of such Act (as added by such section 3)), and on a biennial basis thereafter until October 1, 2027, the
Secretary shall perform an audit of the costs of reviewing such applications under such section 590B. Such an audit shall compare the costs of reviewing such applications under such section 590B to the amount of the user fee applicable to such applications.

(2) ALTERATION OF USER FEE.—If the audit performed under paragraph (1) indicates that the user fees applicable to applications described in such paragraph for a year exceed 30 percent of the costs of reviewing such applications, the Secretary shall adjust the user fees applicable to such applications so that the user fees applicable to such applications for subsequent years do not exceed such percentage.

(3) ACCOUNTING STANDARDS.—The Secretary shall perform an audit under paragraph (1) in conformance with the accounting principles, standards, and requirements prescribed by the Comptroller General of the United States under section 3511 of title 31, United States Code, to ensure the validity of any potential variability.

(e) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out section 3 and the amendments made by such section such sums as may be necessary for each of fiscal years 2018 through 2022.
SEC. 5. CERTIFICATION OF LABORATORIES (CLIA).

Section 353 of the Public Health Service Act (42 U.S.C. 263a) is amended to read as follows:

“SEC. 353. CERTIFICATION OF LABORATORIES.

“(a) Scope of Authority; Definitions.—

“(1) Scope of Authority.—Laboratories shall be regulated by the Secretary under this section. Laboratory operations shall be regulated by the Secretary under this section and shall not be regulated under the Federal Food, Drug, and Cosmetic Act.

“(2) Limitations of Authority.—

“(A) FDA Regulation.—The design, development, validation, production, manufacture, preparation, propagation, and assembly of an in vitro clinical test shall be regulated under subchapter J of chapter V of the Federal Food, Drug, and Cosmetic Act, and shall not be regulated by the Secretary under this section.

“(B) Other Activities.—The Secretary shall not regulate the practice of medicine under this section. The authority to so regulate shall be reserved to the individual States.

“(3) Definitions.—In this section:

“(A) The term ‘certificate’ refers, as applicable, to—
“(i) the documentary evidence of authorization to engage in the activities regulated in this section required under subsection (b); or

“(ii) a certificate of waiver issued under subsection (d)(2).

“(B) The term ‘in vitro clinical test’ has the meaning given to that term in section 201(ss) of the Federal Food, Drug, and Cosmetic Act.

“(C) The term ‘laboratory’ or ‘clinical laboratory’ means a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.

“(D)(i) The term ‘laboratory operations’ means the conduct of a laboratory examination or other laboratory procedure on materials derived from the human body for the purpose described in subparagraph (C), including, the con-
duct of an in vitro clinical test and associated activities not excluded by paragraph (a)(1)(B) from the Secretary’s authority to regulate under this section, within or under the oversight of a laboratory. Such term includes the following activities:

“(I) Developing and implementing standard operating procedures.

“(II) Verifying laboratory performance of an in vitro clinical test.

“(III) Performing pre-analytical, analytical, and post-analytical processes for an in vitro clinical test.

“(IV) Collection, transportation, disposition, and storage of patient specimens.

“(V) Preparing reagents or other test materials which do not meet the definition of a finished test product under section 201(ss) of the Federal Food, Drug, and Cosmetic Act.

“(VI) Performing an in vitro clinical test pursuant to the relevant standard operating procedures for such test.

“(VII) Reporting the output or results of an in vitro clinical test.
“(VIII) Validating changes to in vitro clinical tests if such changes are not regulated under subchapter J of the Federal Food, Drug, and Cosmetic Act.

“(ii) Such term includes the preparation and transfer of individual components, parts, and raw materials between commonly owned laboratories within the same State, if—

“(I) the Secretary has established by regulation—

“(aa) applicable quality requirements that are substantially equivalent to the comparable quality requirements under subchapter J of the Federal Food, Drug, and Cosmetic Act;

“(bb) inspection processes that are substantially equivalent to the comparable inspection processes under such subchapter J; and

“(cc) enforcement processes that are substantially equivalent to the comparable enforcement processes under such subchapter J;

“(II) the Secretary reviews the regulations established pursuant to subclause (I)
three years after the effective date of such regulations to determine whether comparable quality requirements are being implemented as required by such clause and whether the value of such requirements are commensurate with the related burden; and

“(III) as part of the review conducted pursuant to subclause (II), the Secretary—

“(aa) holds at least one public meeting;

“(bb) issues a draft determination regarding whether to maintain or amend the quality requirements established pursuant to subclause (I);

“(cc) provides for a public comment period of 90 days on the draft determination; and

“(dd) issues a final determination, with any proposed amended regulations, not later than four years after the effective date of the regulations established pursuant to subclause (I).
“(E) The term ‘standard operating procedures’ means with respect to an in vitro clinical test, a documented set of instructions, more detailed than the final design of such in vitro clinical test, describing how to perform laboratory operations or to comply with the applicable requirements of this section.

“(b) Certificate Requirement.—No person may solicit or accept materials derived from the human body for laboratory examination or other laboratory procedure unless there is in effect for the laboratory a certificate issued by the Secretary under this section applicable to the category of examinations or procedures which includes such examination or procedure.

“(c) Issuance and Renewal of Certificates.—

“(1) In general.—The Secretary may issue or renew a certificate for a laboratory only if the laboratory meets the requirements of subsection (d).

“(2) Term.—A certificate issued under this section shall be valid for a period of 2 years or such shorter period as the Secretary may establish.

“(d) Requirements for Certificates.—

“(1) In general.—A laboratory may be issued a certificate or have its certificate renewed if—
“(A) the laboratory submits (or if the laboratory is accredited under subsection (e), the accreditation body which accredited the laboratory submits), an application—

“(i) in such form and manner as the Secretary shall prescribe;

“(ii) that describes the characteristics of the laboratory examinations and other procedures performed by the laboratory including—

“(I) the number and types of laboratory examinations and other procedures performed;

“(II) the methodologies for laboratory examinations and other procedures employed; and

“(III) the qualifications (educational background, training, and experience) of the personnel directing and supervising the laboratory and performing the laboratory examinations and other procedures; and

“(iii) that contains such other information as the Secretary may require to determine compliance with this section; and
the laboratory agrees to provide to the Secretary (or if the laboratory is accredited, to the accreditation body which accredited it) a description of any change in the information submitted under clause (ii) not later than 6 months after the change was put into effect;

“(B) the laboratory provides the Secretary—

“(i) with satisfactory assurances that the laboratory will be operated in accordance with standards issued by the Secretary under subsection (f); or

“(ii) with proof of accreditation under subsection (e);

“(C) the laboratory agrees to permit inspections by the Secretary under subsection (g);

“(D) the laboratory agrees to make records available and submit reports to the Secretary as the Secretary may reasonably require;

“(E) the laboratory agrees to treat proficiency testing samples in the same manner as it treats materials derived from the human body referred to it for laboratory examinations or other procedures in the ordinary course of business, except that no proficiency testing sample
shall be intentionally referred to another laboratory for analysis as prohibited under subsection (i)(4); and

“(F) the laboratory has in place processes and policies to review and assess changes or modifications to in vitro clinical tests, as required by paragraph (4).

“(2) REQUIREMENTS FOR CERTIFICATES OF WAIVER.—

“(A) IN GENERAL.—A laboratory which only performs laboratory examinations and procedures described in paragraph (3) shall be issued a certificate of waiver or have its certificate of waiver renewed if—

“(i) the laboratory submits an application—

“(I) in such form and manner as the Secretary shall prescribe;

“(II) that describes the characteristics of the laboratory examinations and other procedures performed by the laboratory, including the number and types of laboratory examinations and other procedures performed, the methodologies for laboratory ex-
aminations and other procedures employed, and the qualifications (edu-
cational background, training, and ex-
perience) of the personnel directing
and supervising the laboratory and
performing the laboratory examina-
tions and other procedures; and

“(III) that contains such other
information as the Secretary may rea-
sonably require to determine compli-
ance with this section; and

“(ii) the laboratory agrees to make
records available and submit reports to the
Secretary as the Secretary may require.

“(B) CHANGES THAT MAY AFFECT WAIVED
STATUS.—

“(i) CHANGES TO CERTAIN EXAMINA-
tIONS AND PROCEDURES.—If a laboratory
makes changes in the examinations and
other procedures performed by it only with
respect to examinations and procedures
which are described in paragraph (3), the
laboratory shall report such changes to the
Secretary not later than 6 months after
the change has been put into effect.
“(ii) OTHER CHANGES.—If a laboratory proposes to make changes in the examinations and procedures performed by it such that the laboratory will perform an examination or procedure not described in paragraph (3), the laboratory shall report such change to the Secretary before the change takes effect. The laboratory shall report any such change to the Secretary without regard to whether such change is a modification subject to premarket approval under section 590B(n) of the Federal Food, Drug, and Cosmetic Act. If any such change is a modification subject to premarket approval under such section 590B(n), the laboratory shall obtain such approval, if required, before putting the modification into effect.

“(iii) HIGH COMPLEXITY.—In the case of any modification by a laboratory to an examination or procedure described in paragraph (3) that causes the examination or procedure to have high complexity, the examination or procedure shall be subject to the requirements under this section for
high complexity examinations and procedures.

“(C) Effect.—Subsections (g) and (h) shall not apply to a laboratory to which a certificate of waiver has been issued.

“(3) Examinations and Procedures.—

“(A) In general.—The examinations and procedures identified in paragraph (2) are laboratory examinations and procedures that have been approved by the Food and Drug Administration for home use or that, as determined by the Secretary, are simple laboratory examinations and procedures that have an insignificant risk of an erroneous result, including those that—

“(i) employ methodologies that are so simple and accurate as to render the likelihood of erroneous results by the user negligible; or

“(ii) the Secretary has determined pose no unreasonable risk of harm to the patient if performed incorrectly.

“(B) Definition.—In this paragraph, the phrase ‘accurate as to render the likelihood of erroneous results by the user negligible’ means,
with respect to an in vitro clinical test, that the accuracy achieved by individuals qualified to perform a laboratory examination or procedure in a laboratory holding a certificate of waiver under paragraph (2) is equivalent to the accuracy achieved by individuals qualified to perform a laboratory examination or procedure in a laboratory certified under paragraph (1), as shown by evidence that directly compares such accuracy or evaluates such agreement of results.

“(e) Accreditation.—

“(1) In general.—A laboratory may be accredited for purposes of obtaining a certificate if the laboratory—

“(A) meets the requirements of this section and meets the standards of an approved accreditation body; and

“(B) authorizes the accreditation body to submit to the Secretary (or such State agency as the Secretary may designate) such records or other information as the Secretary may require.

“(2) Approval of accreditation bodies.—

“(A) In general.—The Secretary may approve a private organization, to be an accred-
if—

“(i) the accreditation body—

“(I) has in place effective conflict of interest provisions;

“(II) uses inspectors trained to use and apply the standards issued by the Secretary under subsection (f) and in the application of other requirements of this section;

“(III) uses inspectors who are qualified to evaluate the methodologies used by the laboratories in performing laboratory examinations and other procedures; and

“(IV) maintains appropriate records;

“(ii) the accreditation body agrees to inspect a laboratory for purposes of accreditation with such frequency as may be determined by the Secretary;

“(iii) the legally binding standards applied by the body in determining whether or not to accredit a laboratory are the
standards issued by the Secretary under subsection (f);

“(iv) there is adequate provision for assuring that the standards issued by the Secretary under subsection (f) and other applicable statutory and regulatory requirements continue to be met by the laboratory;

“(v) in the case of any laboratory accredited by the body which has had its accreditation denied, suspended, withdrawn, or revoked or which has had any other action taken against it by the accrediting body, the accrediting body agrees to submit to the Secretary the name of such laboratory within 30 days of the action taken; and

“(vi) if the accreditation body has its approval withdrawn by the Secretary, the body agrees to notify each laboratory accredited by the body of the withdrawal within 10 days of the withdrawal.

“(B) CRITERIA AND PROCEDURES.—The Secretary shall promulgate criteria and procedures for approving an accreditation body and
for withdrawing such approval if the Secretary determines that the accreditation body does not meet the requirements of subparagraph (A).

“(C) Effect of withdrawal of approval.—If the Secretary withdraws the approval of an accreditation body under subparagraph (B), the certificate of any laboratory accredited by the body shall continue in effect for 60 calendar days after the laboratory receives notification of the withdrawal of the approval, except that the Secretary may extend such period for a laboratory if the Secretary determines that the laboratory submitted an application for accreditation or a certificate in a timely manner after receipt of the notification of the withdrawal of approval.

“(D) Evaluations.—The Secretary shall, beginning one year after the date on which the criteria and procedures are promulgated under subparagraph (B), evaluate annually the performance of each approved accreditation body by—

“(i) inspecting under subsection (g) a sufficient number of the laboratories accredited by such body to allow a reasonable
177

estimate of the performance of such body;

and

“(ii) such other means as the Secretary determines appropriate.

“(E) REPORT.—The Secretary shall, beginning 2 years after the date of the enactment of the Diagnostic Accuracy and Innovation Act, annually prepare and submit to Congress a report describing—

“(i) the implementation of this section during the previous year; and

“(ii) the results of the evaluation conducted under subparagraph (D) for the year covered by the report.

“(3) WITHDRAWAL OR REVOCATION OF LABORATORY ACCREDITATION.—If an accreditation body withdraws or revokes the accreditation of a laboratory, the certificate of the laboratory shall continue in effect—

“(A) for 45 calendar days after the laboratory receives notice of the withdrawal or revocation of the accreditation; or

“(B) until the effective date of any action taken by the Secretary under subsection (j).
“(4) **UPDATED STANDARDS.**—Beginning no later than the effective date of the standards under subsection (f), the regulations for carrying out such standards, and other applicable requirements, approved accreditation bodies shall ensure that—

“(A) the inspectors of such bodies are trained with respect to, and the processes of such bodies are updated in accordance with, such requirements or regulations; and

“(B) any inspection or other review of a laboratory by the approved accreditation body for purposes of accreditation includes a review and assessment of—

“(i) compliance by the laboratory with such requirements and regulations; and

“(ii) whether sufficient processes, policies, organization, and training systems are in place to demonstrate reasonable assurance of future compliance with such requirements and regulations.

“(f) **STANDARDS.**—

“(1) **IN GENERAL.**—The Secretary shall issue standards to assure consistent performance by laboratories issued a certificate under this section of accurate and reliable laboratory examinations and
other procedures. Such standards shall require each laboratory issued a certificate under this section—

“(A) to maintain a quality management system for all phases of the total testing process within, or under the oversight of, the laboratory (consisting of the pre-analytic, analytic, and post-analytic processes) and general laboratory systems adequate and appropriate for the validity and reliability of the laboratory examinations and other procedures of the laboratory and to meet requirements relating to the proper collection, transportation, and storage of specimens and the reporting of results;

“(B) to maintain records, equipment, and facilities necessary for the proper and effective operation of the laboratory;

“(C) in performing and carrying out its laboratory examinations and other procedures, to use only personnel meeting such qualifications as the Secretary may establish for the direction, supervision, and performance of examinations and procedures within the laboratory, which qualifications shall take into consideration competency, training, experience, job performance, and education and which qualifica-
tions shall, as appropriate, be different on the basis of the type of examinations and procedures being performed by the laboratory and the risks and consequences of erroneous results associated with such examinations and procedures;

“(D) to qualify under a proficiency testing program meeting the standards established by the Secretary under paragraph (3);

“(E) to have in place procedures assessing the impact of changes in laboratory operations, equipment, or material on the accuracy and reliability of the examinations and other procedures of the laboratory;

“(F) to have in place quality systems to assess the ability of incoming materials and equipment to meet their intended purposes;

“(G) to meet such other requirements as the Secretary reasonably determines necessary to assure consistent performance by such laboratories of accurate and reliable laboratory examinations and procedures; and

“(H) to have in place processes and policies to review and assess modifications to in
vitro clinical tests in accordance with paragraph (7).

“(2) CONSIDERATIONS.—In developing the standards to be issued under paragraph (1), the Secretary shall, within the flexibility provided under subparagraphs (A) through (H) of paragraph (1), take into consideration—

“(A) the examinations and procedures performed and the methodologies employed;

“(B) the degree of independent judgment involved;

“(C) the amount of interpretation involved;

“(D) the difficulty of the calculations involved;

“(E) the calibration and quality control requirements of the instruments used;

“(F) the type of training required to operate the instruments used in the methodology;

“(G) the regulations issued by the Secretary to carry out subchapter J of chapter V of the Federal Food, Drug, and Cosmetic Act, in order to avoid duplicative requirements; and

“(H) such other factors as the Secretary considers relevant.

“(3) PROFICIENCY TESTING PROGRAM.—
“(A) IN GENERAL.—The Secretary shall establish standards for the proficiency testing programs for laboratories issued a certificate under this section which are conducted by the Secretary, conducted by an organization approved under subparagraph (C), or conducted by an approved accrediting body. The standards shall require that a laboratory issued a certificate under this section be tested for each examination and procedure conducted within a category of examinations or procedures for which it has received a certificate, except for examinations and procedures for which the Secretary has determined that a proficiency test cannot reasonably be developed. The testing shall be conducted on a quarterly basis, except where the Secretary determines for technical and scientific reasons that a particular examination or procedure may be tested less frequently (but not less often than twice per year). Such standards shall include standards for proficiency testing programs for any new specialties and sub-specialties identified under paragraph (5)(A)(ii).
“(B) CRITERIA.—The standards established under subparagraph (A) shall include uniform criteria for acceptable performance under a proficiency testing program, based on the available technology and the clinical relevance of the laboratory examination or other procedure subject to such program. The criteria shall be established for all examinations and procedures and shall be uniform for each examination and procedure. The standards shall also include a system for grading proficiency testing performance to determine whether a laboratory has performed acceptably for a particular quarter and acceptably for a particular examination or procedure or category of examination or procedure over a period of successive quarters.

“(C) APPROVED PROFICIENCY TESTING PROGRAMS.—For the purpose of administering proficiency testing programs which meet the standards established under subparagraph (A), the Secretary shall approve a proficiency testing program offered by a private organization or a State if the program meets the standards established under subparagraph (A) and the organization or State provides technical assistance to
laboratories seeking to qualify under the pro-
gram. The Secretary shall evaluate each pro-
gram approved under this subparagraph annu-
ally to determine if the program continues to
meet the standards established under subpara-
graph (A) and shall withdraw the approval of
any program that no longer meets such stand-
ards, as specified in subsection (e).

“(D) Onsite Testing.—The Secretary
shall perform, or shall direct a program ap-
proved under subparagraph (C) to perform, on-
site proficiency testing to assure compliance
with the standards under this section, in ac-
cordance with paragraph (5). The Secretary
shall perform, on an onsite or other basis, pro-
iciency testing to evaluate the performance of
a proficiency testing program approved under
subsection (C) and to assure quality per-
formance by a laboratory.

“(E) Training, Technical Assistance,
and Enhanced Proficiency Testing.—The
Secretary may, in lieu of or in addition to ac-
tions authorized under subsection (i), (j), or
(k), require any laboratory which fails to per-
form acceptably on an individual examination
and procedure or a category of examinations
and procedures—

“(i) to undertake training and to obtain the necessary technical assistance to meet the requirements of the proficiency testing program;

“(ii) to enroll in a program of enhanced proficiency testing; or

“(iii) to undertake any combination of the training, technical assistance, or testing described in clauses (i) and (ii).

“(F) TESTING RESULTS.—The Secretary shall establish a system to make the results of the proficiency testing programs subject to the standards established by the Secretary under subparagraph (A) available, on a reasonable basis, upon request of any person. The Secretary shall include with results made available under this subparagraph such explanatory information as may be appropriate to assist in the interpretation of such results.

“(4) NATIONAL STANDARDS FOR QUALITY ASSURANCE IN CYTOLOGY SERVICES.—

“(A) ESTABLISHMENT.—The Secretary shall establish national standards for quality as-
surance in cytology services designed to assure consistent performance by laboratories of accurate and reliable cytological services.

“(B) STANDARDS.—The standards established under subparagraph (A) shall include—

“(i) the maximum number of cytology slides that any individual may screen in a 24-hour period;

“(ii) requirements that a clinical laboratory maintain a record of—

“(I) the number of cytology slides screened during each 24-hour period by each individual who examines cytology slides for the laboratory; and

“(II) the number of hours devoted during each 24-hour period to screening cytology slides by such individual;

“(iii) criteria for requiring rescreening of cytological preparations, such as—

“(I) random rescreening of cytology specimens determined to be in the benign category;
“(II) focused rescreening of such preparations in high-risk groups; and

“(III) for each abnormal cytological result, rescreening of all prior cytological specimens for the patient, if available;

“(iv) periodic confirmation and evaluation of the proficiency of individuals involved in screening or interpreting cytological preparations, including announced and unannounced onsite proficiency testing of such individuals, with such testing to take place, to the extent practicable, under normal working conditions;

“(v) procedures for detecting inadequately prepared slides, for assuring that no cytological diagnosis is rendered on such slides, and for notifying referring physicians of such slides;

“(vi) requirements that all cytological screening be done on the premises of a laboratory that is certified under this section;

“(vii) requirements for the retention of cytology slides by laboratories for such
periods of time as the Secretary considers appropriate; and

“(viii) standards requiring periodic inspection of cytology services by persons capable of evaluating the quality of cytology services.

“(5) Uniformity; specialties and subspecialties; errors; harmonization.—

“(A) In general.—The Secretary shall ensure that the standards under this subsection—

“(i) provide nationally uniform standards for the performance of laboratory operations;

“(ii) include—

“(I) standards for specialty and subspecialty testing, including other specialty and subspecialty testing not specifically included as of the date of enactment of the Diagnostic Accuracy and Innovation Act in existing regulations and standards; and

“(II) periodic updates of such standards;
“(iii) include common standards for the identification, investigation, and assessment of laboratory errors and for the corrective and preventive actions appropriate to address such errors;

“(iv) include enhanced quality requirements for preparation of reagents for use not as a finished product but as a component, part, or raw material of an in vitro clinical test performed by the same facility, and for preparation and transfer of individual components, parts, and raw materials between commonly owned laboratories within the same State, to ensure consistent reagent preparation and quality control of the reagent; and

“(v) to the extent possible, be harmonized, in cooperation with the Food and Drug Administration and the Centers for Medicare & Medicaid Services, with other existing standards and best practices, including the accreditation standards of widely recognized professional organizations and the terms, definitions, and stand-

“(B) QUALITY SYSTEM PROCESSES.—The standards under this subsection shall include quality processes for—

“(i) management responsibility and auditing;

“(ii) document controls;

“(iii) purchasing controls;

“(iv) laboratory processes, operations and controls;

“(v) corrective and preventive actions;

“(vi) records; and

“(vii) servicing and maintenance.

“(C) MODERNIZED REGULATIONS.—Not later than the day that is 3 years after the date of enactment of the Diagnostic Accuracy and Innovation Act, the Secretary shall issue final regulations to implement this paragraph.

“(D) RULE OF CONSTRUCTION.—Nothing in subparagraph (A) shall be construed to prohibit an approved accreditation body from establishing and applying standards equal to or more stringent than the standards established
by the Secretary under this section for purposes
of accreditation.

“(E) EFFECTIVE DATE.—The final regula-
tions required to be issued under subparagraph
(C) shall take effect on the date that is 2 years
after the date of issuance of such final regula-
tions. On and after such effective date—

“(i) the Secretary may issue or renew
a certificate for a laboratory under this
section only if the laboratory is in compli-
ance with such regulations; and

“(ii) each laboratory required to be
certified under this section shall comply
with such regulations.

“(6) ADVISORY PANEL.—In proposing and fi-
nalizing regulations under paragraph (5), the Sec-
retary shall utilize the Clinical Laboratory Improve-
ment Advisory Committee or such other advisory
panel, as determined appropriate by the Secretary,
to provide input into the development and content of
such regulations. Such advisory panel shall include,
at a minimum, representatives of laboratories, lab-
oratory operations experts, health care professionals,
professional societies, patient groups, laboratory test
developers, regulatory and quality experts, and public health experts.

“(7) Modifications to in vitro clinical tests.—

“(A) Processes and policies.—A laboratory shall have in place processes and policies to review and assess changes to in vitro clinical tests prior to the implementation of such a change. Such a review and assessment shall be designed to determine whether the proposed change is a modification subject to subchapter J of chapter V of the Federal Food, Drug, and Cosmetic Act and, if so, whether that modification results in a meaningful clinical impact or changes the intended use of the in vitro clinical test so as to be subject to premarket approval or listing under section 590B(n) of such Act.

“(B) Premarket approval or listing.—If the proposed modification has a meaningful clinical impact or changes the intended use of the in vitro clinical test so as to be subject to premarket approval or listing under section 590B(n) of the Federal Food, Drug, and Cosmetic Act, the laboratory—
“(i) shall obtain an approval pursuant to section 590B of the Federal Food, Drug, and Cosmetic Act or, if such an approval is not required, shall list such modification pursuant to section 590B(e) of the Federal Food, Drug, and Cosmetic Act; and

“(ii) shall not implement such modification until such approval is obtained or listing occurs, as applicable, unless otherwise authorized to do so.

“(C) EXCLUSIONS.—Amendments, changes, corrections, or updates to a patient specific laboratory test report—

“(i) shall not be considered a modification that requires review under section 590B(n) of the Federal Food, Drug, and Cosmetic Act; and

“(ii) shall not be treated—

“(I) as labeling under the Federal Food, Drug, and Cosmetic Act; or

“(II) as establishing an intended use for purposes of such Act.

“(g) INSPECTIONS.—
“(1) IN GENERAL.—The Secretary may, on an announced or unannounced basis, enter and inspect, during regular hours of operation, laboratories subject to the requirements of this section. In conducting such inspections, the Secretary shall have access to all facilities, equipment, materials, records, and information that the Secretary determines have a bearing on whether the laboratory is being operated in accordance with this section. As part of such an inspection the Secretary may copy any such material or require it to be submitted to the Secretary. An inspection under this paragraph may be made only upon presenting identification to the owner, operator, or agent in charge of the laboratory being inspected.

“(2) COMPLIANCE WITH REQUIREMENTS AND STANDARDS.—The Secretary shall conduct inspections of laboratories under paragraph (1) to determine their compliance with the requirements of subsection (d) and the standards issued under subsection (f). Inspections of laboratories not accredited under subsection (e) shall be conducted on a biennial basis or with such other frequency as the Secretary determines to be necessary to assure compliance with such requirements and standards. Inspections
of laboratories accredited under subsection (e) shall be conducted on such basis as the Secretary determines is necessary to assure compliance with such requirements and standards.

“(3) Scope of Inspections.—Any inspections conducted pursuant to this section shall be limited to laboratory operations and related issues and shall not include any inspection related to activities regulated under subchapter J of chapter V of the Federal Food, Drug, and Cosmetic Act.

“(h) Intermediate Sanctions.—

“(1) In general.—If the Secretary determines that a laboratory which has been issued a certificate under this section no longer substantially meets the requirements for the issuance of a certificate, the Secretary may impose intermediate sanctions in lieu of the actions authorized by subsection (i).

“(2) Types of Sanctions.—The intermediate sanctions which may be imposed under paragraph (1) shall consist of—

“(A) directed plans of correction;

“(B) civil money penalties in an amount not to exceed $10,000 for each violation listed in subsection (i)(1) or for each day of substantial noncompliance with the requirements;
“(C) payment for the costs of onsite monitoring; or

“(D) any combination of the actions described in subparagraphs (A), (B), and (C).

“(3) PROCEDURES.—The Secretary shall develop and implement procedures with respect to when and how each of the intermediate sanctions is to be imposed under paragraph (1). Such procedures shall provide for notice to the laboratory and a reasonable opportunity to respond to the proposed sanction and appropriate procedures for appealing determinations relating to the imposition of intermediate sanctions.

“(i) SUSPENSION, REVOCATION, AND LIMITATION.—

“(1) IN GENERAL.—Except as provided in paragraph (2), the certificate of a laboratory issued under this section may be suspended, revoked, or limited if the Secretary finds, after reasonable notice and opportunity for hearing to the owner or operator of the laboratory, that such owner or operator or any employee of the laboratory—

“(A) has been guilty of misrepresentation in obtaining the certificate;

“(B) has performed or represented the laboratory as entitled to perform a laboratory ex-
amination or other procedure which is not within a category of laboratory examinations or other procedures authorized in the certificate;

“(C) has failed to comply with the requirements of subsection (d) or the standards prescribed by the Secretary under subsection (f);

“(D) has failed to comply with reasonable requests of the Secretary for—

“(i) any information or materials; or

“(ii) work on materials;

that the Secretary concludes is necessary to determine the laboratory’s continued eligibility for its certificate or continued compliance with the Secretary’s standards under subsection (f);

“(E) has refused a reasonable request of the Secretary, or any Federal officer or employee duly designated by the Secretary, for permission to inspect the laboratory and its operations and pertinent records during the hours the laboratory is in operation;

“(F) has violated or aided and abetted in the violation of any provisions of this section; or

“(G) has not complied with an intermediate sanction imposed under subsection (h).
“(2) Action before a hearing.—If the Secretary determines that—

“(A) the failure of a laboratory to comply with the standards of the Secretary under subsection (f) presents an imminent and serious risk to human health; or

“(B) a laboratory has engaged in an action described in subparagraph (D) or (E) of paragraph (1);

the Secretary may suspend or limit the certificate of the laboratory before holding a hearing under paragraph (1) regarding such failure or refusal. The opportunity for a hearing shall be provided no later than 60 calendar days from the effective date of the suspension or limitation. A suspension or limitation under this paragraph shall stay in effect until the decision of the Secretary made after the hearing under paragraph (1).

“(3) Ineligibility to own or operate laboratories after revocation.—No person who has owned or operated a laboratory which has had its certificate revoked may, within 2 years of the revocation of the certificate, own or operate a laboratory for which a certificate has been issued under this section, except that if the revocation occurs pur-
suant to paragraph (4) the Secretary may substitute intermediate sanctions under subsection (h) instead of the 2-year prohibition against ownership or operation which would otherwise apply under this paragraph. The certificate of a laboratory which has been excluded from participation under the Medicare program under title XVIII of the Social Security Act because of actions relating to the quality of the laboratory shall be suspended for the period the laboratory is so excluded.

“(4) Improper Referrals.—

“(A) In General.—Any laboratory that the Secretary determines intentionally refers its proficiency testing samples to another laboratory for analysis may have its certificate revoked for at least one year and shall be subject to appropriate fines and penalties as provided for in subsection (h).

“(B) Definition.—In this paragraph, the term ‘intentionally refers’ means refers with specific intent to circumvent the proficiency testing requirements of this section.

“(j) Injunctions.—Whenever the Secretary has reason to believe that continuation of any activity by a laboratory would constitute a significant hazard to the public
health the Secretary may bring suit in the district court of the United States for the district in which such laboratory is situated to enjoin continuation of such activity. Upon proper showing, a temporary injunction or restraining order against continuation of such activity pending issuance of a final order under this subsection shall be granted without bond by such court.

“(k) **Judicial Review.**—

“(1) **Petition.**—Any laboratory which has had an intermediate sanction imposed under subsection (h) or has had its certificate suspended, revoked, or limited under subsection (i) may, at any time within 60 calendar days after the date the action of the Secretary under subsection (i) or (h) becomes final, file a petition with the United States court of appeals for the circuit wherein the laboratory has its principal place of business for judicial review of such action. As soon as practicable after receipt of the petition, the clerk of the court shall transmit a copy of the petition to the Secretary or other officer designated by the Secretary for that purpose. As soon as practicable after receipt of the copy, the Secretary shall file in the court the record on which the action of the Secretary is based, as provided in section 2112 of title 28, United States Code.
“(2) ADDITIONAL EVIDENCE.—If the petitioner applies to the court for leave to adduce additional evidence, and shows to the satisfaction of the court that such additional evidence is material and that there were reasonable grounds for the failure to adduce such evidence in the proceeding before the Secretary, the court may order such additional evidence (and evidence in rebuttal of such additional evidence) to be taken before the Secretary, and to be adduced upon the hearing in such manner and upon such terms and conditions as the court may deem proper. The Secretary may modify the findings of the Secretary as to the facts, or make new findings, by reason of the additional evidence so taken, and the Secretary shall file such modified or new findings, and the recommendations of the Secretary, if any, for the modification or setting aside of his original action, with the return of such additional evidence.

“(3) JUDGMENT OF COURT.—Upon the filing of the petition referred to in paragraph (1), the court shall have jurisdiction to affirm the action, or to set it aside in whole or in part, temporarily or permanently. The findings of the Secretary as to the facts,
if supported by substantial evidence, shall be conclusive.

“(4) Finality of Judgment.—The judgment of the court affirming or setting aside, in whole or in part, any such action of the Secretary shall be final, subject to review by the Supreme Court of the United States upon certiorari or certification as provided in section 1254 of title 28, United States Code.

“(l) Sanctions.—Any person who intentionally violates any requirement of this section shall be imprisoned for not more than one year or fined under title 18, United States Code, or both, except that if the conviction is for a second or subsequent violation of such a requirement such person shall be imprisoned for not more than 3 years or fined in accordance with title 18, United States Code, or both.

“(m) Fees.—

“(1) Certificate Fees.—The Secretary shall require payment of fees for the issuance and renewal of certificates, except that the Secretary shall only require a nominal fee for the issuance and renewal of certificates of waiver.

“(2) Additional Fees.—The Secretary shall require the payment of fees for inspections of labora-
tories which are not accredited and for the cost of performing proficiency testing on laboratories which do not participate in proficiency testing programs approved under subsection (f)(3)(C).

“(3) CRITERIA.—

“(A) FEES UNDER PARAGRAPH (1).—Fees imposed under paragraph (1) shall be sufficient to cover the general costs of administering this section, including evaluating and monitoring proficiency testing programs approved under subsection (f) and accrediting bodies and implementing and monitoring compliance with the requirements of this section.

“(B) FEES UNDER PARAGRAPH (2).—Fees imposed under paragraph (2) shall be sufficient to cover the cost of the Secretary in carrying out the inspections and proficiency testing described in paragraph (2).

“(C) FEES IMPOSED UNDER PARAGRAPHS (1) AND (2).—Fees imposed under paragraphs (1) and (2) shall vary by group or classification of laboratory, based on such considerations as the Secretary determines are relevant, which may include the dollar volume and scope of the testing being performed by the laboratories.
“(n) INFORMATION.—On April 1, 1990, and annually thereafter, the Secretary shall compile and make available to physicians and the general public information, based on the previous calendar year, which the Secretary determines is useful in evaluating the performance of a laboratory, including—

“(1) a list of laboratories which have been convicted under Federal or State laws relating to fraud and abuse, false billings, or kickbacks;

“(2) a list of laboratories—

“(A) which have had their certificates revoked, suspended, or limited under subsection (i); or

“(B) which have been the subject of a sanction under subsection (l);

(together with a statement of the reasons for the revocation, suspension, limitation, or sanction;

“(3) a list of laboratories subject to intermediate sanctions under subsection (h) together with a statement of the reasons for the sanctions;

“(4) a list of laboratories whose accreditation has been withdrawn or revoked together with a statement of the reasons for the withdrawal or revocation;
“(5) a list of laboratories against which the Secretary has taken action under subsection (j) together with a statement of the reasons for such action; and

“(6) a list of laboratories which have been excluded from participation under title XVIII or XIX of the Social Security Act.

The information to be compiled under paragraphs (1) through (6) shall be information for the calendar year preceding the date the information is to be made available to the public and shall be accompanied by such explanatory information as may be appropriate to assist in the interpretation of the information compiled under such paragraphs.

“(o) DELEGATION.—In carrying out this section, the Secretary may, pursuant to agreement, use the services or facilities of any Federal or State or local public agency or nonprofit private organization, and may pay therefor in advance or by way of reimbursement, and in such installments, as the Secretary may determine.

“(p) STATE LAWS.—

“(1) IN GENERAL.—Except as provided in paragraph (2), no State, tribal or local government (or political subdivision thereof) may establish or continue in effect with respect to a laboratory, a clinical
laboratory, or laboratory operations any requirement which is different from, or in addition to, any requirement applicable under this section to such laboratory, clinical laboratory, or laboratory operations.

“(2) EXCEPTIONS.—Paragraph (1) shall not be construed to affect the authority of a State, tribal, or local government—

“(A) to license or regulate the terms of licensure of laboratory personnel, health care practitioners, or health care facilities or to regulate any aspect of a health care practitioner-patient relationship; or

“(B) to enforce laws of general applicability, such as zoning laws, environmental laws, labor laws, and general business laws.

“(3) CLARIFICATION.—This section shall not be construed to shift liability to health care practitioners.

“(q) CONSULTATIONS.—In carrying out this section, the Secretary shall consult with appropriate private organizations and public agencies, including the Food and Drug Administration.”.

SEC. 6. TRANSITIONAL PROVISIONS.

(a) CLASSIFICATION.—With respect to an in vitro clinical test that is sought to be first offered after the date
of enactment of this Act, but before the effective date of regulations implementing section 590A of the Federal Food, Drug, and Cosmetic Act, as added by section 3 of this Act, the Secretary shall, by regulation—

(1) classify such in vitro clinical test as a low-risk, moderate-risk, or high-risk in vitro clinical test pursuant to such section 590A; and


(b) QUALITY REQUIREMENTS.—

(1) MANUFACTURERS.—A manufacturer of an in vitro clinical test—

(A) prior to the date of promulgation of final regulations under section 3(e), shall, with respect to such in vitro clinical test, comply with the quality system requirements applicable to devices under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), including part 820 of title 21, Code of Federal Regulations, as in effect on the date of enactment of this Act; and

(B) on or after the date of promulgation of final regulations under section 3(e) and before the effective date of such regulations under sec-
tion 3(e)(2)(A), shall, with respect to such in vitro clinical test, comply with, at the election of the manufacturer—

(i) the quality system requirements described in subparagraph (A); or

(ii) the quality requirements under section 590D of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).

(2) LABORATORY DEVELOPERS.—A laboratory developer of an in vitro clinical test, with respect to activities other than laboratory operations—

(A) prior to the date of promulgation of final regulations under section 3(e), shall, with respect to such in vitro clinical test, comply with any applicable quality requirements under section 353 of the Public Health and Service Act (42 U.S.C. 263a), as in effect on the day before the date of enactment of this Act; and

(B) on or after the date of promulgation of final regulations under section 3(e) and before the effective date of such regulations under section 3(e)(2)(A), shall, with respect to such in vitro clinical test, comply with, at the election of the laboratory developer—
(i) any applicable quality requirements under section 353 of the Public Health and Service Act (42 U.S.C. 263a), as in effect on the day before the date of enactment of this Act; or

(ii) the quality requirements under section 590D of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).

(c) Submission Requirements.—

(1) Manufacturers.—A manufacturer of an in vitro clinical test—

(A) with respect to an in vitro clinical test first offered prior to the effective date of final regulations under section 3(e)(2)(B), shall comply with the approval process under section 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e), the clearance process under section 510(k) of such Act (21 U.S.C. 360(k)), the de novo process under section 513(f)(2) of such Act (21 U.S.C. 360c(f)(2)), or the listing process under section 510(j) of such Act (21 U.S.C. 360(j)), as applicable, in effect on the date of enactment of this Act; and
(B) with respect to an in vitro clinical test first in use on or after the effective date of final regulations under section 3(e)(2)(B), shall comply with the premarket submission requirements of sections 590A, 590B, and 590D of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).

(2) LABORATORIES.—

(A) With respect to an in vitro clinical test first offered on or after the date that is 90 calendar days prior to the date of enactment of this Act, a laboratory developer of such in vitro clinical test shall—

(i) comply with any applicable pre-market requirements pursuant to section 353 of the Public Health and Service Act (42 U.S.C. 263a), as in effect on the day before the date of enactment of this Act; or

(ii) comply with the premarket submission requirements of sections 590A, 590B, and 590D of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).
(B) If a laboratory developer elects to comply with the premarket requirements specified in subparagraph (A)(i), the laboratory developer shall submit to the Secretary postmarket data establishing a reasonable assurance that the in vitro clinical test is analytically valid and clinically valid. Such data shall be provided not later than 3 years after the promulgation of final regulations under section 3(e) and shall be subject to fees pursuant to section 4.

(C) If a laboratory developer elects to comply with the premarket submission requirements specified in subparagraph (A)(ii), the laboratory developer may immediately offer the in vitro clinical test for use but—

(i) not later than the two years after the promulgation of final regulations under section 3(e), the laboratory developer shall comply with such premarket submission requirements; and

(ii) the corresponding application, notification, or listing for the in vitro clinical test shall not be subject to fees pursuant to section 4.

(d) POSTMARKET REQUIREMENTS.—
(1) MANUFACTURERS.—A manufacturer of an in vitro clinical test—

(A) prior to the date of promulgation of final regulations under section 3(e), shall, with respect to such in vitro clinical test, comply with the postmarket requirements applicable to devices under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), including part 803 of title 21, Code of Federal Regulations, as in effect on the date of enactment of this Act; and

(B) on or after the date of promulgation of final regulations under section 3(e) and before the effective date of such regulations under section 3(e)(2)(A), shall, with respect to such in vitro clinical test, comply with, at the election of the manufacturer—

(i) the postmarket requirements applicable to devices under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), including part 803 of title 21, Code of Federal Regulations, as in effect on the date of enactment of this Act; or

(ii) the postmarket requirements under section 590E of the Federal Food,
Drug, and Cosmetic Act, as added by section 3(a).

(2) LABORATORY DEVELOPERS.—A laboratory developer of an in vitro clinical test, with respect to activities governed by this Act and the amendments made by this Act other than laboratory operations—

(A) prior to the date of promulgation of final regulations under section 3(e), shall, with respect to such in vitro clinical test, comply with any applicable postmarket requirements under section 353 of the Public Health and Service Act (42 U.S.C. 263a), as in effect on the day before the date of enactment of this Act; and

(B) on or after the date of promulgation of final regulations under section 3(e) and before the effective date of such regulations under section 3(e)(2)(A), shall, with respect to such in vitro clinical test, comply with, at the election of the laboratory developer—

(i) any applicable postmarket requirements under section 353 of the Public Health and Service Act (42 U.S.C. 263a), as in effect on the day before the date of enactment of this Act; or
(ii) the postmarket requirements under section 590E of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).

(e) DEFINITIONS.—In this section:

(1) The term “developer” has the meaning given to such term in section 590 of the Federal Food, Drug, and Cosmetic Act, as added by section 3(a).

(2) The term “device” has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321).

(3) The term “finished product” has the meaning given to such term in section 201(ss) of the Federal Food, Drug, and Cosmetic Act, as added by section 2.

(4) The term “in vitro clinical test” has the meaning given to such term in section 201(ss) of the Federal Food, Drug, and Cosmetic Act, as added by section 2.

(5) The term “laboratory developer” means a laboratory that is the developer of—

(A) an in vitro clinical test first offered prior to the date that is 90 calendar days prior to the date of enactment of this Act for which
the Secretary did not require an approval under section 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e), a clearance under section 510(k) of such Act (21 U.S.C. 360(k)), or notification under section 510(j) of such Act (21 U.S.C. 360(j)) or otherwise asserted enforcement discretion with regard to such sections; or

(B) an in vitro clinical test first offered on or after the day that is 90 calendar days prior to the date of enactment of this Act for which, prior to such day, the Secretary would not have required an approval under such section 515, a clearance under such section 510(k), or notification under such section 510(j) or otherwise would have asserted enforcement discretion with regard to such sections.

(6) The term “manufacturer” means the developer of an in vitro clinical test other than a laboratory developer.